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Research on bone regeneration began decades ago as a result of intensive studies on bone growth 
and healing. Bone has been recognised, among the many tissues in human body, as having the 
highest potential for regeneration 1, and it is the second most transplanted tissue following blood 2. 
Due to both internal mediators and external mechanical demands, it possesses the intrinsic ability 
for regeneration and is constantly engaged in a cycle of resorption and renewal undergoing 
continual chemical exchange and structural remodelling throughout adult life as well as during 
repair process in response to injury. Despite these abilities, beyond a critical point clinical 
intervention measures are needed; there are different clinical conditions requiring a large quantity 
of bone regeneration, such as for skeletal reconstruction of large bone defects created by trauma, 
infection, or cases in which the regenerative process is compromised, including necrosis, atrophic 
non-unions and osteoporosis. 
To describe the extent of this situation, it is estimated that annually more than 2.2 million patients 
receive bone defect repairs worldwide 3, with a cost greater than $2.5 billion just in the United 
States; this figure is expected to globally double by 2020 due to a variety of factors, including 
increased life expectancy 4,5. The board of the Bone and Joint Decade in 2009 has assessed that half 
of the people aged over 65, affected by chronic conditions, suffers of joint diseases and that the 
number of osteoporotic fractures has doubled in the previous 15 years 4,6. It should be also pointed 
out that the worldwide incidence of bone disorders and conditions is increasing in those societies 
where population ageing is combined with increased obesity and poor physical activity 6. 
Shortcomings, limitations, and complications of current clinical treatments for bone repair and 
regeneration have been reported in different studies 7,8. A variety of graft materials are currently 
used to enhance bone healing, and the relative success of these materials depends on many factors, 
not only on the specific properties of the graft itself. In addition to its physical properties, to be 
effective, a grafting material is required to even provide osteoconductive and/or osteoinductive 
activities. Osteoconduction, the ability of promoting bone growth by allowing bone formation on 
material’s surface, may suffice in clinical condition of less severe defects, where sufficient quantities 
and margins of bone exist. Osteoinduction instead, is the capability of promoting de novo bone 
formation at soft or hard tissue sites, and offers needful advantages for biologic reconstruction of 
severe situations.  
Among most commonly used materials there are allografts, cadaveric bone usually obtained from a 
bone bank, autologous grafts, bone harvested from the patient’s own body, or synthetic ones, often 
made of hydroxyapatite or other naturally and biocompatible substances.  
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Allografts, mineralized or demineralized, are histocompatible, available in various forms including 
demineralized bone matrix and cortical grafts and whole-bone segments, depending on the host-
site requirements, and provide an osteoconductive environment; however, their osteoinductive 
capacity is highly variable depending on the processing method and sourcing, and may be present 
in inadequate amounts for any bone-inductive effect 9. 
To date, autografts serve as the gold standard for bone grafts because they are histocompatible, 
non-immunogenic, and they offer all of the properties required. Specifically, this material provides 
an osteoconductive environment (i.e., three-dimensional scaffolds and porous matrix) coupled with 
cells (i.e., osteoprogenitor cells) as well as growth and differentiation factors(i.e., growth factors) 
that can result in osteoinduction 10. Nevertheless, autogenous grafting is sometimes an expensive 
procedure that has a number of shortcomings, including the need for secondary surgery to harvest 
the graft, donor site morbidity, irregular resorption of transplanted tissue, and limited availability of 
donor bone 11,12. Furthermore autograft may be a useless or inadequate treatment option in cases 
where the defect site requires larger amounts of bone than is available. 
Other commonly used bone repair techniques involve synthetic materials and fillers, and growth 
and differentiation factors, but, although all these clinical interventions have been shown to 
improve bone repair, none of them possess all of the necessary characteristics: high osteoinductive 
and angiogenic potentials, biological safety, low patient morbidity, ready access to surgeons, no size 
restrictions, long shelf life and reasonable cost; all these limitations have led to an extensive 
research for alternatives.  
The discovery and subsequent production of the osteoinductive agents in bone, the Bone 
Morphogenetic Proteins (BMPs), have provided the possibility of reducing or avoiding the need 
for autograft, through a tissue-engineering product.  
Clinically, BMPs have demonstrated the potential to replace the use of autogenous bone in many 
applications so that costs and complications related to harvesting autograft can be prevented 13; in 
addition, the ability to control quality, activity and dose of the osteoinductive agent may provide 
greater assurance of bone induction and repair. Despite this, a widespread therapeutic use of BMPs 
has been hindered by difficulties in obtaining large amounts of pure, biologically active protein at a 
cost-effective price 13. 
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Thus, the aim of this study was to develop a plant based system for cost-effective production of 
active recombinant BMPs. This introduction provides a review of the relevant literature pertaining 
to BMPs (especially to BMP-2) synthesis, processing and recombinant production process. 
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1.1 Bone Morphogenetic Proteins. 
As early as 1889 Senn observed that decalcified bone could induce healing of bone defects in dogs 
14. Later Levander provided the first evidence of ectopic bone formation after injecting bone crude 
extracts into muscle 15,16. In 1965 a pioneering work by Urist established a landmark on the research 
in bone regeneration: he discovered that demineralized bone fragments are able to induce new bone 
formation by autoinduction when implanted either subcutaneously or intramuscularly in a study 
that involved more than 300 animals 17. Urist discovered that the active compound responsible for 
bone formation was a mix of proteins and proposed the name "Bone Morphogenetic Protein" in 
the scientific literature in the Journal of Dental Research in 1971 18. 
In the years that followed, fundamental steps 
were made by Reddi and his colleagues, who 
proposed that BMPs are responsible for the 
initiation of a cascade of developmental 
events, in which progenitor cells in the bone 
marrow were induced to produce bone cells 
leading to bone regeneration 19–21. 
In 1981 Reddi created a reproducible bioassay 
for BMP mediated ectopic bone formation, 
that was based on the activity of the Alkaline 
Phosphatase (ALP) enzyme and on the 
content of calcium in the newly formed bone 
21. Moreover they observed that 
demineralization of the bone matrix in the 
solid state with dissociative extractants, that 
contained protease inhibitors in order to 
solubilize putative inductive molecules, resulted in the loss of the bone inductive property of the 
matrix, and that there was a complete recovery of biological activity after reconstitution of the 
residues with the extracts, thus demonstrating BMP to be part of the extracellular matrix of bone 
and showing unequivocally that the extracellular matrix of bone is a reservoir of morphogenetic 
soluble signals that per se are able to initiate the cascade of bone differentiation by induction 21–23. 
Figure 1: Cellular events after implantation of 
BMP. These proteins induce both endochondral 
and direct bone formation; the result in each case is 
woven bone that then remodels and becomes 
populated with hematopoietic bone marrow. 
This figure is taken from Wozney, Spine 2002 10. 
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The cellular events caused by BMP have been described by histological examination of BMPs 
implanted subcutaneously in a rat assay system 20,24. These include chemotactic action, that mediate 
the infiltration of the implant site with cartilage and bone cell precursors, proliferative events, the 
differentiation of precursor cells into chondrocytes, the induction of vascularisation of the site, the 
maturation of the chondrocytes and the differentiation of cells into osteoblasts (Figure 1). This 
complex process results in a new piece of bone tissue, complete with osteoblasts, osteocytes, 
osteoclasts, and bone marrow elements 20,25. A steep dose–response curve is observed, with low 
doses resulting in small amounts of cartilage and bone formation; however, at no concentration 
stable cartilage formation was observed, being cartilage always replaced by bone 26. Larger doses, 
instead, result in more substantial bone formation and earlier osteoinduction 26. Interestingly, when 
higher concentrations of BMPs are applied, bone forms at the same time as cartilage formation, 
suggesting that BMP can result in direct (intramembranous) ossification 10,26. The great work of 
Urist and Reddi provided the reproducible evidence of the osteogenic activity of demineralized 
bone and dentine matrices, implying the presence of morphogenetic factors and, as per Urist 
speculation, of a bone morphogenetic protein complex within the bone matrix 18,21. Despite these 
results, the characterization of this elusive complex has been hindered by the limited quantities of 
putative proteins within the extracellular matrix of bone, tightly bound to the organic and inorganic 
components of the bone matrix 27. The purification process of BMP from bone includes: the 
removal of the mineral component of bone with acid, the extraction of the active component from 
the remaining organic matrix of bone using chaotropic agents, and then multiple column 
chromatography steps performed with the material in guanidine or urea due to the insolubility of 
the extract. This procedure results in a very low and still not pure yield. 28,29. 
During the decades of 80s and 90s, the BMPs genes were cloned and the recombinant proteins 
demonstrated to be biologically potent 29,25. Recombinant BMPs (rhBMPs) were used first time in 
late 90s for clinical applications such as spinal fusion, fracture healing and dental tissue engineering 
30–33. Human rhBMPs are currently manufactured using mammalian cell-line expression by 
recombinant technology. Briefly, a production cell line was generated by placing the DNA coding 
sequence of BMP in a vector system that contains appropriate promoter enhancer sequences for 
protein expression; this vector is then transfected into a mammalian cell host, such as Chinese 
Hamster Ovary (CHO) cells for rhBMP-2; after a characterization step to ensure fidelity of 
expression, the cell line is expanded in sequentially larger volumes of culture medium and 
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thousands of liters of the BMP-expressing cells in medium can be obtained. The protein is then 
purified from the conditioned medium. As mammalian cells are used to synthesize these BMPs, 
the obtained molecules are dimerized, processed and glycosylated like the human ones 34. The 
advantages of this recombinant production system include the reproducibility, the ability to ensure 
purity and activity of the proteins and the guarantee of a freedom from impurity products, but the 
production process is expensive. 35. In 2002 the Food and Drug Administration (FDA) gave 
approval of two recombinant products containing rhBMP-2 and rhBMP-7 (also known as 
Osteogenic Protein-1, OP-1) in absorbable collagen carriers for spinal fusion and long bone non-
unions 36–39. 
1.1.1 Properties and Classification 
BMPs are members of the transforming growth factor beta (TGF-β) superfamily of secreted 
growth and differentiation factors 40,41. The BMP subfamily comprises at least fifteen proteins: 
BMP-2, BMP-3 (also known as Osteogenin), BMP-3b (also known as Growth and 
Differentiation Factor 10, GDF-10), BMP-4, BMP-5, BMP-6, BMP-7 (OP-1), BMP-8 (OP-2), 
BMP-9, BMP-10, BMP-11 (also known as GDF-8 or Myostatin), BMP-12 (also known as 
GDF-7), BMP-13 (also known as GDF-6), BMP-14 (also known as GDF-5), and BMP-15 42,1. 
BMP-1 is a type I procollagen C-proteinase and doesn’t belong to the TGF- β family 43. Based on 
the amino acid (AA) sequence homologies of the mature domains, members of the BMP family are 
further divided into sub-families (Figure 2) 42. Among these groups, BMP- 2 and BMP-4 have 
92% AA sequence homology of molecules, and BMP5, BMP-6, BMP-7, and BMP-8 have 78% 
AA sequence homology. Between these two groups there is a 55% to 65% sequence homology of 
mature proteins 25,44. 
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Extensive research has shown that several BMPs, but not all, induce ectopic bone or cartilage 
formation; The physiologic roles of the BMPs include pivotal roles during embryonic development 
in the specification of the positional information and the development of organs and the 
requirement for skeletal and nonskeletal tissue formation.45,40. Analysis of gene knockouts, in which 
one or more BMP genes are inactivated, indicate some redundancy in the BMP family 46. 
However, each BMP appears to have a unique role in the formation of one or more tissue types 47.  
1.1.2 Receptor and Signaling 
BMP dimers, like others members of the TGF-β superfamily, induce signaling binding with a 
heterotetrameric receptor complex consisting of two different types (Type 1(BMPR-1) and Type 2 
(BMPR-2)) of serine-threonine kinase receptors, known as BMP receptors42,48. 
Even if Type 1 and Type 2 receptors can individually bind BMP, both type of receptors are 
indispensable for signal transduction 49; ligands have to bind both receptors to form a high-affinity 
heteromeric ligand-receptor complex in order to initiate BMP-dependent intracellular signaling 
through the Smads, a family of intracellular signaling proteins 50. 
The overall structures of Type 1 and Type 2 receptors are similar; they are composed of three parts: 
a short extracellular domain with 10-12 conserved cysteine residues, a single transmembrane 
domain and an intracellular domain with serine/threonine kinase motif 42. Preceding the 
serine/threonine kinase domain, Type 1 receptors, but not Type 2 receptors, have a domain which 
contains a characteristic SGSGS motif (GS domain), which plays an important role in signal 
transduction 48. In mammals, BMPs bind two different Type 1 receptors, BMP receptor Type 1A 
(BMPR-1A, also denoted Activin receptor-like kinase (ALK)-3) and Type 1B receptors (BMPR-
1B, also called ALK-6), in presence of BMP Type 2 receptors 48,51. The structures of the two BMP 
Type 1 receptors are similar, but they activate Smad proteins in a partly different pattern 52. In the 
TGF-β receptor system, ligands bind to Type 2 receptors even in the absence of Type 1 receptors, 
but Type 1 receptors can bind ligands only in the presence of Type 2 receptors 53; However, 
whereas BMP Type 1 receptors are able to bind ligands even in the absence of Type 2 receptors, 
the binding to Type 1 receptors is facilitated by the presence of the Type 2 51,54. So, signal 
transduction for BMPs requires both receptors: Type 1 receptors are activated by Type2 and signals 
are mediated through Type 1; thus, signal specificity is determined by Type 1 receptors 55. 
Members of the BMP family show different binding affinities to different combinations of Type1 
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and Type 2 receptors, and these differences may be related to the overlapping but strictly different 
functional effects of BMPs 42,56. 
On the inside of the cell membrane, BMPs activate the intracellular signalling through a receptor 
regulated class of Smads (tumor-suppressor Smad proteins), a family of eight intracellular signaling 
proteins phosphorylated by Type 1 receptor kinase 55; in this way, receptors for different factors are 
able to transmit specific signals along the pathway (Figure 3). 
There are three types of Smads: signal-transducing receptor-regulated Smads or R-Smads (Smad1, 
Smad5, and Smad8), common mediator Smad or Co-Smad (Smad 4 and Smad 3) and inhibitory 
Smads or I-Smads (Smad 6 and Smad 7). BMP receptors are able to target R-Smads; the 
phosphorylation of these proteins induces their association with a Co-Smad, and the formation of 
heterodimeric complexes induce their accumulation in the nucleus, where they recruit transcription 
factors, co-activators and co-repressors in order to regulate the transcription of target genes by 
binding to specific DNA sequence 50. BMP targets the genes of tissue-determining transcription 
factors that promote differentiation of Mesenchymal Stem Cells (MSCs) toward the osseous cell 
phenotypes 57. 
 
Figure 3: BMP binding and intracellular signal transduction 42,55. A BMP dimer binds with the BMP receptors 
(BMPR). Following binding, BMPR-2 phosphorylates BMPR-1 and activates intracellular signaling through the 
Smads. R-Smads forms heterodimeric complexes with Co-Smad and enter the nucleus where alter the transcription 
of target genes. BMP antagonists can bind with BMP and inhibit the signal cascade. I-Smads can bind with 
BMPR-1 to prevent it from phosphorylating R-Smads. Smurf interacts with R-Smads and mediates the degradation 
of these proteins. In the nucleus, there are a number of co-activators and co-repressors that control the transcription 
of the target gene. 
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Between the transcription factors present in the nucleus two are specific targets for BMP signalling: 
Core Binding Factor Alpha 1 (Cfba1) and Osterix. Mice with a homozygous mutation in Cbfa1 
died just after birth without breathing; examination of their skeletal systems showed a complete 
lack of ossification caused by the maturational arrest of osteoblasts, demonstrating that Cbfa1 plays 
an essential role in osteogenesis 58,59. Cfba1 and Osterix expression is upregulated by the R-
Smads/Co-Smad complex (the complex increase the level of mRNA expression) 60–62. For example, 
after stimulation by BMP-2, Smad1 protein is phosphorylated mainly on serine residues and, 
associated with Smad4, translocated into the nucleus where it induces Osterix expression 57,63. 
Smad6 and Smad7, instead, are I-Smad and were shown to bind BMPR-1B inhibiting the 
phosphorylation of Smad1, suggesting that this class of Smad members could interfere with BMP 
signalling 52,64. 
i. Regulation 
BMP signaling can be tightly modulated at many levels (Figure 3). Extracellularly, soluble 
antagonists proteins, such as Noggin, Chordin, Gremlin, and Follistatin, can bind only some 
BMPs, inhibit their binding to cell surface receptors and prevent the signal cascade 50. Noggin and 
Chordin were shown to be able to directly bind BMP-4 and BMP-2 and prevent the interaction 
with the receptors 65,66; Follistatin was instead shown to bind BMP-7, acting as an inhibitor 67. 
Moreover it has been found that BMPs can upregulate the expression of some of these inhibitors, 
suggesting a negative feedback loop that limits the activity of BMPs. The Tolloid Drosophila gene, 
on the contrary, encodes a metalloprotease similar to BMP-1 that was shown to inhibit Chordin 
activity by proteolytically cleavage, acting therefore as a coactivator of BMPs 68. 
Intracellularly, the activity of BMPs can be modulated by the activation of I-Smads or by Smurf 1 
(Smad ubiquitin regulatory factor, an ubiquitin ligase). As said before, I-Smads can bind with 
BMPR-1 to prevent it from phosphorylating R-Smads and the subsequent heteromerization with 
Co-Smad 52,69; again, BMPs can upregulate expression of I-Smad proteins. Instead Smurf1 
selectively interacts with receptor-regulated Smads (Smad1/5), specific to the BMP pathway, in 
order to trigger their ubiquitination and degradation, and hence their inactivation, thus inhibiting 
the transmission of BMP signals 70. In addition, a number of regulators of BMP action exist within 
the nucleus 50. All of these regulatory mechanisms together cause the bone-induction process to be 
controlled tightly and self-limiting 55. 
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1.1.3 Physiological Function 
BMPs are a family of multifunctional proteins. Implantation of osteogenic BMPs, such as BMP-2, 
at an osseous or extraosseous site results in bone and cartilage formation 29; in contrast, BMP-3 is 
known to be an inhibitor of bone and cartilage formation 71. As mentioned before, these molecules 
are soluble, local-acting signaling proteins. In vivo, BMPs act primarily as differentiation factors, 
turning responsive mesenchymal cells into cartilage- and bone-forming cells 72. This is supported 
by many in vitro studies showing that the BMPs turn on specific markers of the osteoblast or 
chondroblast phenotype in a number of cells; for example, rhBMP-2 induces the expression of 
Osteocalcin, a bone specific protein, in the W-20–17 bone marrow stromal cell line, ROB-C26 
calvarial cells, and C3H10T1/2 embryonic cells 72,73. In addition to inducing differentiation, BMPs 
can also change the phenotype of some cell types, in particular fat and muscle cells, into that of the 
osteoblastic lineage; the myoblastic cell line C2C12 stops expression the myoblast lineage markers 
and induces expression of the osteoblast lineage markers in response to rhBMP-2 74. 
BMPs activities can be categorized into two fundamental physiological functions: the skeletal and 
organogenic ones. 
i. Skeletal Function 
When implanted in vivo BMPs initiate a complex series of cellular events culminating in cartilage, 
bone, and other connective tissue formation 41,75. It has been demonstrated that BMPs can regulate 
growth and differentiation of several cell types 72; BMPs 2, 4, 5, 6, 7, and 8 are growth and 
differentiation factors that can individually induce de novo bone formation both in vitro and at 
heterotopic sites in vivo 34. BMP-2 was the first of them that showed its ability to induce the 
formation of new cartilage and bone tissues, demonstrating that members of this class of molecules 
were sufficient for osteoinduction 26. BMPs induce bone formation by promoting the 
differentiation of MSCs in the bone marrow into osteoblasts and enabling the proliferation of 
osteogenic cells 10. The injection of BMP-2 locally, over the surface of calvaria of mice, induces 
periosteal bone formation on the surface of calvaria without a prior cartilage phase 76. The over-
expression of a dominant-negative truncated BMPR-1B in osteoblast precursor cells inhibits 
osteoblast-specific gene expression and mineralized bone matrix formation 77. Transgenic mice in 
which expression of a dominant negative truncated BMPR-1B transgene is targeted to the 
osteoblast lineage using the osteoblast-specific Type I collagen promoter, demonstrated a decreased 
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postnatal bone formation 78. All these results together demonstrate that BMPs and their signalling 
receptor play a necessary role in physiological postnatal bone formation 70. 
Osseous wound healing requires instead the induction of mesenchymal stromal cells to differentiate 
along the osteoblastic lineage for new bone formation. BMPs expression by osteoblastic cells has 
been demonstrated in vivo and in vitro, however, during fracture healing the immunolocalization 
of BMP-2 and BMP-4 revealed their limited expression in a small number of primitive cells of the 
fracture callus 79 and their secretion by macrophages 80; this data suggest a “domino effect”, where 
cells produce BMPs in order to activate other osteoprogentior cells, which produce more BMPs 81. 
ii. Organogenic Functions 
BMPs are also involved in a number of non-osteogenic developmental processes, regulating 
growth, differentiation, chemotaxis and apoptosis of cells. These proteins play pivotal roles during 
embryonic development by specification of the positional information in the embryo and the 
requirement for skeletal and nonskeletal tissue formation, in the development of several organs and 
tissues including the nervous system, tooth buds, eye, lung, kidney, prostate, gonads, and hair 
follicles 40. Moreover it was well demonstrated that during embryonic development, BMP 
expression by non-osteoblastic cells results in osteoinduction and bone morphogenesis, and that 
mesenchymal cells in developing tissues are influenced by BMP prior to any innate ability to 
produce BMP themselves 82. 
Analysis of gene knockouts demonstrated that the elimination of BMP-7 gene results in 
developmental abnormalities of the kidney and eye, with skeletal deficits 83. Because BMP-2 is 
required much earlier in embryonic development mice deficient for BMP-2 are nonviable: 
homozygous BMP-2 mutant embryos die between embryonic day 7.5 and 10.5 and have defects in 
cardiac development, manifested by the abnormal development of the heart in the exocoelomic 
cavity 24,84.  
1.1.4 Clinical Applications of BMPs 
As said before, the repair and replacement of bone is a major clinical problem. The need for 
functional treatments of fracture non-unions, spinal injuries, and bone loss associated with trauma 
and cancer has become increasingly common and remains a significant challenge in surgery 6. 
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The osteoinductive capacity of BMPs has been demonstrated in preclinical models and evaluated in 
clinical trials 85, and nowadays two rhBMP-based commercial products are on market. OP-1™ 
(rhBMP-7, Stryker Biotech, Hopkinton, MA), a rhBMP-7 bioimplant, was the first BMP to be 
approved by the Food and Drug Agency (FDA) in 2001 for the treatment of long bone non-unions 
36. today, OP-1® is also approved for use in spinal fusion surgeries 39. Infuse® (rhBMP-2, 
Medtronic, Minneapolis, MN), a rhBMP-2 bioimplant, is approved by regulatory agencies for 
spinal fusion, tibial fracture repair and for maxillary sinus and alveolar ridge grafting 37,38. 
 
rhBMPs were used in clinical setting at a pharmacologic dose; their pleiotropic effects may be due 
to a threshold paradigm, in which a low threshold dose of fentomolar concentration is optimal for 
chemotaxis, a nanomolar range supports mesenchymal cell proliferation, and a low micromolar 
concentration promotes bone differentiation 20. Since the half-life of rhBMP-2 is about 6-7 min 
(tested on non-human primates) due to enzymatic degradation and rapid clearance rate, to increase 
its effectiveness of healing non-union fractures, rhBMPs are often combined with biocompatible 
carriers such as absorbable collagen sponges 86,87. Loading rhBMP into an absorbable collagen 
sponge (ACS) allows for a gradual proteins release over time, which stimulates new bone formation 
in the implant site more effectively 33. In addition to collagen-based scaffolds, calcium phosphate 
scaffolds have shown promise for use in spinal fusion surgery 88; since calcium phosphates can 
provide structural support and osteoinductivity, composite scaffolds composed of BMP-2 loaded 
collagen and calcium phosphate have been studied and shown a great potential89,90. rhBMP-2 
delivery and subsequent spinal fusion has also been mediated by biocompatible polymers like 
polylactide-co-glycolide (PLGA) 91 and polyether-ether-ketone (PEEK) 92. Specifically, CD-
Horizon®, a PEEK-based material made by Medtronic that is supplemented with rhBMP-2 and a 
Table 1: FDA-approved clinical applications of recombinant BMP-2 and BMP-7. 
Recombinant BMP 
isoforms 
rhBMP-2 rhBMP-7 
FDA approval 
-Spinal fusion (anterior lumbar 
interbody fusion) 
-Open tibial fractures 
-Sinus lift 
-Alveolar ridge augmentation 
*-Spinal fusion (posterolateral lumbar 
fusion) 
*-Long bone non-union 
 
  *Under a humanitarian device 
exemption (HDE). 
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compression resistant matrix composed of calcium phosphate and collagen has been shown to 
enhance spinal fusion in a Phase III clinical trial 93.  
Current clinical applications of rhBMP-based products include spinal fusion, long bone non-
unions, and oral and craniomaxillofacial surgeries 94,95 (see the resume in Table 1). 
 
i. Spinal Surgery 
Recombinant human BMP-based therapies have greatly enhanced the outcomes of spinal fusion 
surgery 96. This procedure is typically conducted in order to reduce pain associated with abnormal 
vertebrae motion or to treat spinal deformities; the gold standard graft for spinal fusion surgery has 
been harvested tissue from the iliac crest which, unfortunately, can often lead to significant pain 
and morbidity at the donor site 97. For these reasons synthetic grafts coupled with BMPs have been 
shown to be clinically viable alternatives.  
rhBMP-2 has been studied extensively in preclinical spine fusion models in several species, 
including non-human primates, demonstrating rhBMP-2 to be equivalent or, in some cases, 
superior to autogenous bone 31. These results led to the first human prospective, randomised, 
multi-centre clinical trial that involved 279 patients with degenerative disc disease (DDD) 98. in 
that study rhBMP-2/ACS was added to cortical allografts and it was shown to induce better 
anterior lumbar interbody fusion (ALIF) results when compared to iliac crest autografts leading to 
clearance by the FDA for this application in 2002 38,99. Spine surgeons then began to develop 
surgical techniques for conducting interbody fusion procedures through posterior lumbar interbody 
fusion (PLIF) and, later, through transforaminal lumbar interbody fusion (TLIF) procedures. A 
clinical trial that involved 67 patients with single-level DDD treated with cylindrical threaded 
cages filled with either rhBMP-2/ACS or iliac crest autograft using a PLIF procedure 
demonstrated a better fusion rate for rhBMP-2/ACS 100. A similar result was obtained in a study 
on TLIF procedures on 40 patients 101. More recent studies on the use of rhBMP-2/ACS in 
single- and multi-level posterolateral spine fusions have shown less complications, decreased need 
for additional treatment or revision surgery, cost less to treat and an equivalent fusion rate than 
patients who received an ileac crest bone graft 102,103. Similar to rhBMP-2, rhBMP-7 showed the 
capacity to mediate enhanced spinal fusion. To date, research evaluating rhBMP-7 as an 
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osteoinductive protein for spinal applications shown itself to be safe and effective for the treatment 
of posterolateral lumbar fusion and cervical non-unions 39,104. 
BMP dose escalation studies in animal models have indicated that 3 to 3.5 mg of BMP is sufficient 
in virtually all cases of spinal fusion to induce new bone and to bridge the osseous defect, and 
additional doses do not lead to any benefit in terms of fusion rate or the time taken for the fusion 
to occur 105. 
ii. Fractures and Bone Non-Unions  
Long bone fractures make up a large portion of clinically reported fractures5. While many long 
bone fractures can be repaired without surgery, a significant portion of fractures are considered 
critical-size defects, meaning they commonly form non-unions without a surgical intervention with 
a bone graft to assist the repair and regeneration. Autografts or allografts are often used, but 
recently, after many preclinical studies that clearly demonstrated the capability of rhBMP-2/ACS 
to induce new bone formation in a number of different orthotropic locations in animal models, 
BMP-loaded implants have become more frequently utilized in clinical practice 106. The pivotal 
study on this field was a large clinical study performed in 2002 by a group of surgeons collectively 
named the BMP-2 Evaluation in Surgery for Tibial Trauma Study Group (BESTT) on 450 
patients, showing that rhBMP-2 loaded collagen sponges greatly benefited patients undergoing 
severe, open tibial fracture repair surgeries 106. Overall, in this study 74% of rhBMP-2/ACS 
patients healed without secondary intervention compared to 54% of control patients 106. Further 
analyses showed that rhBMP-2/ACS patients had fewer hardware failures and significantly faster 
fracture healing than control patients, as confirmed even by a subsequent analysis performed on a 
subgroup patients with the most severe fractures. 106,107. These results lead to FDA approval in 
2004 for the treatment of acute, open tibial fractures 37. Moreover, a follow-up economical analysis 
on the BESTT study in the United Kingdom, Germany, and France found that the medical cost-
savings of the BMP-2 loaded sponges outweighed their product cost 108. With the demonstrated 
ability of rhBMP-2/ACS to induce bone formation there has been interest in applying rhBMP-
2/ACS to other orthopaedic trauma applications. In a randomised, controlled, prospective clinical 
trial, that compared rhBMP-2/ACS combined with cancellous allograft to iliac crest autograft in 
tibial fractures with critical bone loss, the fractures healed in 13 of 15 patients in the rhBMP-2 
group and 10 of 15 in the autograft group 109. 
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Clinical trials using rhBMP-7 for fracture repair started nearly 20 years ago and, like rhBMP-2, 
also rhBMP-7 has shown clinical benefits in promoting long bone fracture healing 110. In 2001, 
rhBMP-7 was approved by the FDA under the Humanitarian Device Exemption (HDE) for the 
use in long bone non-unions 36. The early studies showed that collagen sponges loaded with 
rhBMP-7 have the same effectiveness in healing tibial fracture non-unions as autografts and that 
they were able to induce bone healing in critical-size fibular defects similar to demineralized bone 
matrix 110. These results have been supported by more recent studies that used rhBMP-7 to guide 
repair of a wide-range of non-unions (tibial, femoral, humeral, ulnar, and radial) with an high 
fusion rate 111.  
iii. Dental and Maxillofacial Surgery 
Bone grafts are utilized to repair mandibular and maxillofacial defects caused by traumatic injuries, 
congenital defects, or surgeries for tumor removal 112; moreover they could be also required in order 
to create a solid base for dental implants 113. As already mentioned, autologous bone grafts 
harvested from various body districts, such as the tibia, ilium or chin, are considered the gold 
standard for almost all bone surgical procedures, even in oral and maxillofacial reconstructions. 
However, after the rhBMP-2 bone graft FDA approval for oral and maxillofacial surgeries 
requiring a large amounts of bone, such as for sinus augmentations, for alveolar ridge 
augmentations, or for defects associated with extraction sockets, rhBMP products are 
recommended by surgeons as an alternative to autografts, used alone or in combination to other 
bone substitute materials 114. 
Similar to spine and trauma application, prior to FDA approval, preclinical and clinical research 
was performed to examine feasibility, safety and efficacy of using rhBMP-2/ACS for the treatment 
of common oral maxillofacial defects in a number of animal species (included monkeys) and 
humans 30,115. First important steps were made in 2003, when a feasibility study on sinus floor 
augmentation was performed in order to test a single rhBMP-2 concentration (0.43 mg/cc) on 
ACS, demonstrating that it  was successful at inducing bone formation in a non-human primate 
segmental defect model 116.  
After this encouraging result, Boyne performed a large randomised, controlled, rhBMP-2 dosing 
phase II study for maxillary sinus floor augmentation 117. Patients were treated with either two 
different concentrations of rhBMP-2/ACS or with bone allograft as control; histological bone core 
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biopsies taken at the time of dental implant placement demonstrated normal bone growth and CT 
scan bone density readings were comparable between all treatment groups following 6 months of 
functional loading 117. After identifying 1.5 mg/cc of rhBMP-2 as the most effective concentration, 
a large randomised, multi-centre, pivotal study was performed examining the safety and efficacy of 
rhBMP-2/ACS in sinus floor augmentations 118. A total of 160 patients were treated with either 
1.5 mg/cc rhBMP-2/ACS or autogenous bone graft; CT scans prior to and following implant 
placement and bone core biopsies for histological analysis were analysed, demonstrating that both 
groups experienced significant formation of new trabecular bone that was biologically and 
structurally similar to the host site and an implant success rates comparable between groups, 
concluding that rhBMP-2 and autograft groups performed similarly 118.  
Similar results were found in a large clinical study performed on patients requiring extraction socket 
augmentation; the results demonstrated that sites treated with rhBMP-2/ACS had about two times 
the amount of bone compared to the empty control group; in addition core bone biopsies showed 
no differences between the rhBMP-2-induced bone and native one 119.  
These research studies demonstrated that rhBMP-2/ACS at 1.5 mg/cc concentration is effective at 
inducing viable de novo bone formation capable of implant osseointegration and functional loading 
of dental prostheses 120. 
Despite this positive data, compared to spinal fusion and non-union fractures, there are limited 
cases of clinical studies involving oral and maxillofacial surgeries using rhBMPs, probably due to an 
unfavourable cost/effective ratio 13. 
1.2 Biosynthesis, Processing and Secretion in Eukaryotes 
Proteins constitutes more than half of the total dry mass of a cell, and their synthesis is 
fundamental to cell maintenance, growth and development 121. The synthesis starts when a 
molecule of mRNA (messenger RNA) is copied from the genomic DNA that encodes for a specific 
protein and binds a ribosome in the cytoplasm 122; ribosomes, interacting with tRNA (transfer 
RNA), mediate the translation of proteins from the nucleotide sequences to the amino acid one 123. 
Most of the proteins intended for secretion (like BMPs), or membrane-bound, or that will reside in 
an organelle, use a pathway named “co-translational translocation”. It means that these proteins 
present an N-terminal signal peptide that is recognized by a Signal Recognition Particle (SRP) 
Valentina Ceresoli – R09501 
 
Production of Human Recombinant Differentiation Factors in Transgenic Tobacco Plants 
In
tr
od
uc
ti
on
 
22 
while the protein is still being synthesized on the ribosome; this recognition pauses the synthesis 
while the ribosome-protein complex is transferred to a specific receptor on the endoplasmic 
reticulum (ER), where the nascent protein is inserted through a translocon complex named Sec61 
124. A schematic outline of the organelles that compose the exocytotic pathway in eukaryotic cells is 
presented in (Figure 4) 125. It comprise the ER, which is in continuity with the nuclear envelope, 
the Golgi apparatus, the endosomal/lysosomal system, the secretory granules, the plasma 
membrane and various type of vesicular intermediates that mediate the dynamic connection 
between these compartments 126,127. 
The ER is the entry site of the pathway and, as said before, targeting to this compartment is 
mediated by various type of targeting sequence existing in mRNA of proteins 124. In the ER 
proteins undergo various co- and post-translational modification, including proteolitic cleavage, 
glycosylation, folding, and formation of disulfide bonds 128. If proteins are properly folded they can 
exit the ER 129; the passage of proteins from the ER to their final localization involves sequential 
transit through a series of compartments, collectively referred as the Golgi complex, mediated by 
carrier vesicles that bud from each compartment and then fuse with the next 127. The Golgi 
apparatus is organized into three functionally distinct (but physically associated) regions and is a 
 
Figure 4: The eukaryotic secretory pathway. Secretory proteins enter the membrane trafficking 
system by (a) translocation from the cytoplasm into the endoplasmic reticulum (ER) (b) In the 
ER, proteins are packaged into ER to Golgi complex (GC) carrier vesicles that (c) deliver proteins 
to the GC. As proteins progress through the GC they become (d) glycosylated. Once the (e) reach 
the /trans-Golgi network (TGN), they (f) are sorted into secretory vesicles in which proteins are 
(g) transported to the plasma membrane (PM). At the cell surface secretory proteins are (h) 
released into the extracellular environment. 
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complex and dynamic organelle that plays a pivotal role in controlling trafficking and sorting of 
proteins to various branched routes in the exocytotic pathway 130. 
The Golgi apparatus is organized into three sub-compartments regions; the cis-Golgi network 
(CGN), the medial Golgi (or Golgi stack) and the trans-Golgi network (TGN). The CGN and 
the TGN are the entry and exit faces of the stack, respectively, and are primarily sorting and 
distribution centres. The CGN, located on the cis side and including the cistenae and the vacuolar 
elements linked to the cis side of Golgi apparatus, serves mainly as a filter to remove misfolded or 
uncorrected proteins 130,131. The stack cisternae functions as a series of different processing stations 
that are involved protein modifications, such as the maturation of the saccharide side chain, as well 
as in forwarding the anterograde traffic to the TGN 127. The TGN, composed by an extensive 
tubular/vesicular network on the trans side of the Golgi apparatus, is where proteins with different 
final destinations diverge to their final destinations 132; these include the transport to secretory 
granules, to the endosomal/lysosomal system and the plasma membrane 133. This mechanism has 
been confirmed by examining epithelial cells in vitro: it has been found that proteins from ER 
destined for secretion travel together until they reach the trans Golgi network, where proteins are 
separated and dispatched in vesicles to the appropriate plasma membrane domains 134. In general, 
there are two pathways of protein secretion in eukaryotes: the constitutive and the regulated 
pathways 135. In the constitutive pathway, proteins are transported in vesicles to the cell surface at a 
constant rate without storage or regulation; the vesicles then fuse with the plasma membrane to 
release their contents by exocytosis 135. In the regulated pathway instead, newly synthesized proteins 
destined for secretion are stored at high concentration in secretory vesicles until the cell receives an 
appropriate stimulus. Unlike the transport vesicles of constitutive secretory cells, secretory vesicles 
are prevented from fusing with the plasma membrane until the level of a cytoplasmic messenger is 
altered 135. 
For BMP synthesis, the DNA encoding BMP is first transcribed into mRNA in the nucleus. 
Then, the mRNA is translated by ribosomes into amino acids (AAs) to form a precursor BMP 
polypeptide. To mature into dimeric BMP, the newly synthesized proBMP has to go through a 
series of post-translational modifications before finally being secreted outside the cell.  
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1.2.1 Biosynthesis of BMPs 
Like other molecules of the TGF-β family, the BMPs are synthesized as pre-pro-peptides of 
approximately 400 to 525 amino acid (AA) in length25,40,42. The pre-pro-peptide consists of an 
amino terminal hydrophobic secretory signal peptide, a pro-domain, and a carboxyl terminal 
mature protein. The mature domain of all BMPs contains in their primary structure seven highly 
preserved cysteine residues. Six of these cysteines form a rigid “cysteine-knot”, a structural motif 
that is highly conserved for all members of the TGF-β  superfamily 136,137,41. A cysteine knot is a 
structural signature that describes disulfide connectives in which two pairs of disulfide bridges form 
a ring through which a third disulfide bridge is threaded. The 7th cysteine, instead, is involved in 
linking two BMP monomers to form a dimer. Three of the BMP family members, BMP-2, BMP-
4, and BMP-7 do not contain cysteine residues in their propeptides; the presence of cysteine 
residues required for dimerization of the propeptide have been implicated in the formation of a 
latent (inactive) complex between TGF-ββ and its precursor 138. This indicates that probably these 
three BMPs are secreted in active forms.  
 
1.2.2 Post-Translational Modifications of BMPs 
There are different types of post-translational modifications. These can be grouped into: 
modification of AAs (such as by addition of phosphate, acetate, or various lipids and 
 
Figure 5: General Scheme of processing of BMP. Signal sequence of pre-pro-BMP is first cleaved. Two proBMP 
monomers dimerize in the endoplasmic reticulum of the cell. Then the dimer is transported to the trans Golgi 
network where individual pro-domains are cleaved by an enzyme (e.g. furin). Finally the mature BMP-2 dimer is 
secreted into extracellular space. (Wozney et al., 1990)25 
Dimerization 
Pro-Domain Mature Domain 
Pro-Domain Mature Domain 
Pro-Domain Mature Domain Pro-BMP2 
Pre-Pro-BMP2 Signal Peptide Pro-Domain Mature Domain 
Mature BMP-2 
Dimer 
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Mature Domain 
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carbohydrates) or modifications resulting in structural changes (like the formation of disulfide 
bonds, or proteolytic cleavage) 121. Pre-pro-BMPs have to go through several post-translational 
modifications before they can be secreted as active proteins.  
 
i. Dimerization 
BMP proteins are active as dimer molecules 25. They can form either homodimers (made up of 
monomers of a single BMP subfamily member) or heterodimers (made up of monomers of two 
different BMP subfamily members) connected by a disulfide bond in a head-to-tail arrangement in 
the ER 139. Transient co-expression of BMP-2 with either BMP-5, BMP-6 or BMP-7, or BMP-4 
transiently co-expressed with BMP-7, resulted in greater BMP activity than expression of any 
single BMP 140; particularly, under certain conditions, heterodimers of BMP-2 and BMP-7 are 
more osteoinductive than the corresponding homodimers 140. Currently, both rhBMP therapeutic 
formulations (rhBMP-2 or Infuse® and rhBMP-7 or OP-1®) are composed of BMP homodimers. 
ii. Glycosylation 
Glycosylation, a factor affecting solubility of proteins, is another major post-translational 
modification with significant effect on protein folding, conformation, stability and activity, that 
begins in the ER and continues in Cis-Golgi 121. Carbohydrates in the form of Asparagine-linked 
(N-linked) or Serine/Threonine-linked (O-linked) oligosaccharides are major structural 
components of many secreted proteins. In N-linked glycosylation, the oligosaccharide chain is 
attached by an oligotransferase to Asparagine (Asn) in the tri-peptide sequence Asn-X-Ser, Asn-
Table 2: Primary sequence of a full-length human BMP-2 precursor shows signal peptide, pro-domain 
and mature BMP-2 region. 
1 MVAGTRCLLA LLLPQVLLGG AAGLVPELGR RKFAAASSGR PSSQPSDEVL SEFELRLLSM 
61 FGLKQRPTPS RDAVVPPYML DLYRRHSGQP GSPAPDHRLE RAASRANTVR SFHHEESLEE 
121 LPETSGKTTR RFFFNLSSIP TEEFITSAEL QVFREQMQDA LGNNSSFHHR INIYEIIKPA 
181 TANSKFPVTR LLDTRLVNQN ASRWESFDVT PAVMRWTAQG HANHGFVVEV AHLEEKQGVS 
241 KRHVRISRSL HQDEHSWSQI RPLLVTFGHD GKGHPLHKRE KRQAKHKQRK RLKSSCKRHP 
301 LYVDFSDVGW NDWIVAPPGY HAFYCHGECP FPLADHLNST NHAIVQTLVN SVNSKIPKAC 
361 CVPTELSAIS MLYLDENEKV VLKNYQDMVV EGCGCR   
Two cleavage sites RISR (S2 site)and REKR (S1 site) are both located on the pro-domain (underlined and bolded). 
Seven cysteines involved in cysteine knot and dimerization are located within the mature domain (bolded, 
underlined and red). There are three potential N-linked glycosylation sites in pro-domain and one in the mature 
region (highlighted in yellow). 
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X-Thr, or Asn-X-Cys, where X can be any AA, except Proline 121. BMPs are glycosylated proteins 
141. Unlike TGF-β, all the mature BMP proteins contain between one and three potential N-linked 
glycosylation sites 142; the propeptide portion also contains potential N-linked glycosylation sites, 
similar to TGF-β 25. A glycosylation site in the centre of mature protein domain is shared by 
BMPs 2, 4, 5, 6, 7, and 8, but is absent in BMP-3 that has a single glycosylation site at the C-
terminus of the mature domain 44.  
BMP-2 has one glycosylation site in the mature domain (see Table 2), instead BMP-7 has three 
potential sites. Recombinant BMPs produced in mammalian cells are post-translationally modified 
through N-linked glycosylation, ensuring correct folding e activity of the protein 35; on the 
contrary, lack of glycosylation lead to a decrease in solubility of BMPs that might be useful to 
enhance the retention of rhBMPs in organic matrices in order to allow for lower BMP doses to 
induce bone formation, as first animal study suggests 143. 
iii. Proteolytic Cleavage 
BMPs, like many other proteins and like all TGF-β family members , are first synthesized as 
inactive precursor proteins, which are then turned into the active form via proteolytic cleavage of a 
multibasic amino acid motif to yield a C-terminal active peptide 25,144. This processing event has 
been proposed to regulate the secretion and/or the diffusion of BMPs, thereby controlling the 
range over which these molecules can signal during embryonic development 145. Organisms often 
use pro-proteins when the subsequent protein is potentially harmful, but needs to be available on 
short notice and/or in large quantities 121. The cleavage of pro-proteins begins in the trans Golgi 
network and it continues in the secretory vesicles and sometimes in the extracellular fluid after 
secretion has occurred 121. Precursors of BMP are cleaved by proteases that belong to the 
Proprotein Convertase (PC, or Subtilisin-like Proprotein Convertases (SPCs)) family 144. Pro-
protein convertases are calcium-dependent serine proteases that process a wide variety of pro-
protein substrates in eukaryotic cells. They have been shown to cleave at either specific single or 
pairs of basic residues of the general formula (Arg/Lys)–Xn–(Arg/Lys), where n = 0, 2, 4, or 6 146. 
In mammals, seven members of this family have been characterized and different studies have 
revealed that in some cases, more than one PC is able to cleave the same substrate 144; for instance, 
radiolabeled proBMP-4 incubated with four different PCs in vitro was cleaved by Furin and PC6, 
but not by PACE4 and PC7 144. This suggests that there may be some overlap in the activity of 
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PCs 147. The number of cleavage sites varies with different BMPs. For example, both BMP-2 and 
BMP-4 have two cleavage consensus sites named S1 and S2 26,35, while BMP-7 possesses only one 
consensus site 148. For the BMPs with more than one cleavage site, the order of cleavage may be 
fundamental; studies have demonstrated that proBMP-4 is cleaved in a sequential manner 144,149. 
Cleavage at the S1 site adjacent to the mature domain of BMP-4 allows for the subsequent 
cleavage at an upstream S2 site within the pro-domain. Study on a mutant form of proBMP-4 with 
modified S2 site showed that it was cleaved at S1 site to generate 18 kDa mature protein, but the 
cleaved pro-domains were 35 kDa (larger than the normal 32 kDa pro-peptides because they 
retains the S1-S2 peptide), indicating that the S2 site cleavage was required to generate 32 kDa 
pro-peptides. A mutated proBMP-4 with disrupted S1 site was completely resistant to cleavage by 
Furin, despite containing the native S2 site 149. From these results, it emerges that cleavage at the 
S1 site is required for subsequent S2 site cleavage. 
Despite proBMP-2 and proBMP-4 have identical cleavage sites, an optimal cleavage site REKR 
(Arg-Glu-Lys-Arg, named S1 site) and a minimal cleavage site RISR (Arg-Ile-Ser-Arg, named S2 
site) (see Table 2), only recent published works demonstrate that PC6, during decidualization, 
processes proBMP-2 into mature and biologically active BMP-2 150. Nevertheless, it is very likely 
that Furin as well is one of the enzymes that can process proBMP-2. Due to the similarity of 
cleavage site specificity between the PCs and their overlapping expression in different tissues, it is 
often difficult to assign cleavage of a given precursor to particular convertases and, as told before, it 
is also probable that more than one PC is involved in proteolytic cleavage of a BMP. 
Like other highly related proteins, mature TGF-β is well known to be secreted by most cell types 
in noncovalent association with a disulfide-linked homodimer of its pro domain, masking its 
activity and prolonging its in vivo half-life 151. It has been reported that after cleavage, even BMPs 
pro-domain may remain bound to the mature domain non-covalently, thus forming a large 
complex 35,152; whether or not the pro-domain remains noncovalently associated with processed 
BMP-2 has not been established, but is known that an in-frame deletion of the pro-peptide of 
BMP-2 yielded a polypeptide that was not secreted from the cell, suggesting that the pro-peptide 
may therefore be involved in processing and secretion of mature BMP-2 protein 35.  
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1.2.3 Secretion of BMPs 
BMPs are secretory proteins; however, little is known about BMP secretion. Considering their 
synthesis as pro-proteins and the presence of multiple basic AA motif Arg-X-Lys/Arg-Arg among 
various BMPs (e.g. BMP-2/4/7), BMPs may be secreted through the constitutive secretory 
pathway, like TGF-β1, another member of the TGF-β superfamily 153. However, currently, there is 
no direct evidence that supports that BMPs are also secreted from the constitutive pathway. 
1.3 Recombinant Protein Production for Pharmaceuticals 
Once a rarely used subset of medical treatments, protein therapeutics have increased greatly in 
number and frequency of use since the introduction of the first recombinant protein therapeutic, 
human insulin, 30 years ago 154. Only a small number of proteins are expressed in their native cell 
type under physiological conditions in amounts that permit convenient purification of the relatively 
large quantities required for research and clinical use; accordingly, various expression systems have 
been developed to produce recombinant products. In the late 1970s and early 1980s recombinant 
proteins began to be produced and tested, and during last decades several of them reach the market 
under a strict regulation 155. In USA certain of them, like insulin and human growth hormone, were 
regulated by the Centre for Drug Evaluation and Research under the Federal Food, Drug, and 
Cosmetic (FDC) Act as drugs, and others, like cytokines, proteins that are involved in the immune 
response, and blood factors, such as factor VIII for the treatment of haemophilia were regulated by 
the Centre for Biologics Evaluation and Research under the Public Health Service (PHS) Act 155. 
Compared to many small molecule drug products, proteins are usually larger and complex 
molecules, which, however, have several advantages, mainly because proteins often serve a highly 
specific and complex set of functions that cannot be mimicked by simple chemical compounds 154. 
Particularly, the specificity of proteins activity is an advantage because there is less potential for 
protein therapeutics to interfere with normal biological processes and consequently cause adverse 
effects, and because the body naturally produces these proteins, so there is less chance to elicit 
immune responses. Protein therapeutics can also provide effective replacement treatment for 
diseases in which a gene is mutated or deleted, without needing for gene therapy, which is not 
currently available for most of genetic disorders. A study published in 2003 showed that the average 
clinical development and approval time was more than 1 year faster for 33 protein therapeutics 
approved between 1980 and 2002 than for 294 small-molecule drugs approved during the same 
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time period, demonstrating that clinical development and FDA approval time of protein 
therapeutics is faster than that of chemical drugs 156. This makes proteins very attractive from a 
commercial perspective for companies that could be able to obtain far-reaching patent protection 
for protein therapeutics. 
Close monitoring operated by the FDA is necessary because even well-characterized, highly 
purified recombinant proteins may exhibit minor degrees of structural variability between different 
batches resulting from variations depending on condition of the source material, processes used to 
extract and purify the product, and other factors. It is fundamental to remember that the amino 
acid sequence is the most rudimentary characteristic of a protein; thus technologies based on 
peptide mapping, protein sequencing, and mass spectroscopy are not sufficient to lead to an FDA 
approval. Other structural complexities that must be evaluated include: folding of the protein's 
amino acid chain into organized structures, post-translational modification of the protein and, 
eventually, association of multiple protein molecules into aggregates. It is the combination of 
amino acid sequence and structural properties that give a protein its specific activity, and the 
functional characterization using in vitro and in vivo tests is also mandatory during the process of 
development. Potential immunogenicity is another important issue that needs to be strictly 
investigated; an immune response to a therapeutic protein can range from development of 
detectable but not clinically significant antibodies, to an immune response with impact on safety or 
effectiveness 155. 
Despite this strict control, to date, more than 100 recombinant proteins with human therapeutic 
use produced from single cell expression systems have entered the market, and more than 350 are 
under development, demonstrating usefulness and benefits of this technology 154,157,158. 
1.3.1 Common Problems Encountered During Production of 
Recombinant Proteins 
Even nowadays, when hundreds of proteins are produced at commercial scale, their production still 
constitutes a challenge in many cases 157; moreover, many applications would benefit with higher 
production efficiencies and consequent lower costs of the final product. 
Typical problems encountered during recombinant protein production concern loss of expression, 
inefficient post-translational processing and inadequate final localization of the proteins. 
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i. Loss of Expression 
A necessary condition for adequate recombinant protein production is the efficient expression of 
the gene of interest; however, expression can be lost due to structural changes in the recombinant 
gene or disappearance of the gene from host cells. The gene of interest can be located in plasmids, 
or integrated to the host’s chromosome, or delivered by a virus, and the strategies in order to avoid 
a loss of expression are different 157. 
• Plasmid-Based Systems 
Plasmids are extrachromosomal self-replicating cytoplasmic DNA elements that have been used as 
molecular vehicles for recombinant genes since the dawn of genetic engineering because of their 
easy genetic manipulation. Plasmid-based expression is the most popular choice when using 
prokaryotes as hosts, and plasmid copy number is an inherent property of each expression system 
and depends on the kind of plasmid, the host, and the culture conditions159,160. In particular, 
plasmid copy-number is regulated by copy-number control genes and it can range from a few up to 
200 161; the metabolic load imposed by plasmids presence increases with increasing in the size of 
the insert, temperature, expression level, recombinant protein yield, and toxicity of the expressed 
protein toward the host 162. As copy number increases, the metabolic load increases, consequently, 
growth rate decreases  and faster-growing plasmid-free cells eventually overtake the culture 162. 
Plasmid loss is the main cause of reduced recombinant protein productivity in plasmid-based 
systems; an unequal plasmid distribution upon cell division, called plasmid segregational instability, 
will eventually lead to plasmid-free cells, depending from a random distribution between daughter 
cells 161. The higher the number of plasmid copies, the lower the probability of a plasmid-free 
daughter cell. 
Another factor that induce loss of expression is plasmid multimerization, an event that occurs when 
plasmid copies having the same sequence recombine forming a single dimeric circle with two 
origins of replication. This results in fewer independent units to be segregated between daughter 
cells, and consequently plasmid loss can increase 163. It is possible to prevent plasmid instability by 
adding a competitive advantage for plasmid-bearing cells over plasmid-free cells; the strategy most 
commonly used is to introduce into the plasmid a gene that provides resistance to particular 
antibiotics 164. Unfortunately, a large use of antibiotics has many disadvantages, because they are 
expensive and their presence is undesirable in food and therapeutic products as well as in the 
exhausted culture broth that is discharged to wastewater treatment facilities of large scale 
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fermentation operations. Accordingly, other forms of selective pressure have been explored, such as 
deletion of an essential gene from the bacterial chromosome and its inclusion in the plasmid, or the 
introduction of a growth repressor in the bacterial genome and its antidote in the plasmid 165. 
Another important issue in plasmid-based systems is plasmid copy number. Although high plasmid 
copy numbers are generally used for improving recombinant protein yield, this might not always be 
true. For instance, high copy numbers may drive high protein production rates, which can result in 
protein aggregation and deficient posttranslational modification 165. Low recombinant protein 
yields can also occur in cells with a high plasmid copy number, possibly because of a reduction in 
translation efficiency. Accordingly, different production strategies should be chosen for different 
plasmid copy numbers in order to obtain a productive process.  
• Chromosomal Integration 
Chromosome integration is the strategy of choice for the commercial expression of recombinant 
proteins by mammalian cells. In this case, the long and intricate procedure invested in host 
development is easily compensated with a stable host 166. This strategy is a powerful alternative for 
overcoming problems of expression stability in plasmid-based systems, even though there are 
several disadvantages. Indeed, adequate integration of a foreign gene in host’s chromosome is 
intricate and time-consuming. Still, a major problem encountered with chromosomal integration is 
the possibility that the gene of interest will become integrated into an inactive region of chromatin, 
moreover, chromosome integration typically results in lower production rates than with plasmid-
based systems due to a low copy number of the recombinant gene 167. Nevertheless,  methods for 
obtaining multiple gene integration into the chromosome that yield similar expression levels to 
those achieved by plasmid systems have been described and the recombinant cells obtained are able 
to grow in the absence of antibiotics without any reduction of recombinant protein yields 168. 
• Viral Vectors 
Viral vectors are an easy and effective way of delivering genes in host’s cells. Some of them, such as 
retroviruses, promote stable integration of the viral genome into cell’s chromosome, others are used 
for transient expression, but in the second case recombinant protein production occurs only during 
certain stages of the life cycle of the virus. The simplicity of virus-driven protein expression system 
makes it useful even for stable production in higher eukaryotes, like animal or plant cells, avoiding 
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longer cloning procedure. Instead, transient expression is often utilized for rapidly generating little 
amounts of protein for laboratory scale applications or for preliminary testing of drug candidates 169. 
Viral expression systems may also be used for industrial protein production; for example, nowadays, 
Baculovirus Expression Vector System (BEVS) is utilized to commercially produce several 
recombinant proteins and especially vaccines 170. It is mandatory that the products must be virus-
free guaranteed, thus, special considerations are required during purification operations. The use of 
viral vectors involves a process with two different phases: first, cells are grown to a desired cell 
density, and then they are infected with the virus of interest. One of the most important limitations 
of expression systems based on viral vectors is the quality of the viral stock because of the necessary 
serial in vitro passaging can result in the appearance of so called Defective Interfering Particles 
(DIP), viruses that had  several genome deletions that make their replication faster than that of 
intact ones. Therefore, DIP compete for the cellular machinery and can drastically reduce 
recombinant protein yields. As DIP replication requires a helper virus, in this case the complete 
intact virus, their accumulation can be avoided by using lower Multiplicities of Infection (MOI) in 
order to limit the probability that both an intact virus and a defective one will infect the same cell 
171. The Time of Infection (TOI) refers to the cell concentration at which virus is added to the 
culture and it is an important parameter: it should be late enough to allow for sufficient 
accumulation of cells, but should be early enough for nutrients to remain in an abundant 
concentration to sustain recombinant protein production. The MOI and TOI are closely related 
and should be selected carefully depending on the particular characteristics of the system of 
interest. In addition to MOI and TOI, culture conditions can also affect the infection process 169. 
A direct relation between the amount of virus attached to cells and recombinant protein 
concentration has been observed; thus, infection strategies should be aimed at increasing virus 
attachment, which in turn depends on cell concentration, medium composition, temperature, 
viscosity, and amount of cell surface available for infection 169. 
ii. Post-translational Processing 
As already mentioned, post-translation modifications are an essential step in protein biosynthesis. 
Most of mammalian proteins need a complex pattern of modifications (e.g. proteolitic cleavage, 
glycosylation, folding) in order to achieve their functional activity; but not all the expression 
systems are able to resemble their mammalian counterparts. 
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While microbial systems, have the advantage of low cost in establishing a production strain, quick 
production cycle, easy in-process control, and high productivity, the bulk of recent biologics have 
been produced in mammalian cell lines due to the requirement for post translational modification 
and the biosynthetic complexity of the target proteins. Nowadays mammalian cell expression has 
become the dominant recombinant protein production system for clinical applications because of 
its capacity for post-translational modification and human protein-like molecular structure 
assembly 172. 
• Folding, Aggregation, and Solubility 
When folding does not proceed adequately, maybe because of cell stress, it results in misfolded 
proteins that accumulate in intracellular aggregates known as inclusion bodies.173. Production of 
inactive proteins represents an energetic drain and metabolic load, while accumulation of inclusion 
bodies can cause structural strains to the cell. Accordingly, incorrect protein folding has adverse 
consequences. Even the overexpression of heterologous proteins often results in the formation of 
inclusion bodies, mainly because recombinant proteins often reach concentrations higher than 
physiological ones, which may promote aggregation 174. During heterologous protein production, 
high rates of expression are required causing the saturation of the cellular folding machinery 175; so, 
a rapid intracellular protein accumulation and the expression of large proteins increase the 
probability of aggregation 165. 
However aggregation is not necessarily a trouble; indeed, it could be an useful way in order to 
protect proteins from proteolysis and speed their recovery by lysis of the cells and precipitation of 
the inclusion bodies by centrifugation 165. In addition, when potential toxicity of the expressed 
protein to the host is suspected, this deleterious effect can be prevented by producing it as inclusion 
bodies 176. Accordingly, in some circumstances, inclusion body formation can be promoted directly 
through molecular biology or operation strategies, such as the use of protease-deficient strains, or 
culturing at high temperatures, or designing suitable fusion peptides through protein engineering 
approaches 174. In some cases, as for insulin and growth hormone, recovery and renaturation 
operations can be performed in an economically feasible manner 165; however, refolding is an 
empirical process that could be very inefficient, with yields lower than 10%, thus, every case need a 
careful evaluation of advantages and disadvantages of a solubilisation of the proteins 177. Moreover, 
it is almost impossible to predict whether a protein will aggregate or not in a particular expression 
system for sure, or how easily it will be solubilized and renaturated, thus, soluble proteins 
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production is generally preferred 165. A strategy used in order to facilitate protein folding and 
reduce aggregation is cloning of chaperones and foldases into hosts 175; however, since it is not 
possible to predict which chaperone will facilitate folding of a particular protein, the overexpression 
of more than one chaperone has been explored with satisfactory results 174,175. Protein engineering 
can also reduce aggregation by changing the extent of hydrophobic regions or using fusion 
proteins174; both these strategies allow the production of soluble functional protein in the hosts 178.  
• Proteolytic Processing 
When recombinant proteins are expressed in host system, its sequence could include fragments, 
like the signal peptide or the pro-domain, that are needed in order to direct proteins to the various 
cellular compartments or to permit the correct folding, but that must be cleaved to obtain a 
functional protein. The signal peptide, for example, is removed upon membrane translocation, by a 
signal peptidase complex that is membrane-bound to the ER in eukaryotes or to the cellular 
membrane in prokaryotes 181; an inefficient removal of it may result in protein aggregation and 
retention within incorrect compartments and, consequently, the yields of secreted proteins can be 
reduced. Study on overexpression of signal peptidase, the enzyme responsible for signal peptides 
removal, in bacteria, demonstrates an increasing of the release of mature recombinant secretory 
proteins 182. Despite these promising results, signal peptidase overexpression in bacteria has rarely 
been used 157. 
Other proteins, such as proteases or insulin, must be expressed as pro-proteins because their pro-
domains act as folding catalysts 183; in these cases, cells utilize endoproteases to produce a mature 
active protein 184. Overexpression in mammalian and insect cells of the mammalian endoprotease 
furin increased the concentration of correctly folded product demonstrating itself a viable option to 
increase recombinant proteins production 185. 
• Glycosylation 
Glycosylation is a complex post-translational modification that requires several steps and enzymes 
and that determines protein stability, solubility, antigenicity, folding, localization, biological 
activity, and circulation half-life. As told before it usually occurs in the ER and cis-Golgi apparatus 
of eukaryotic cells 130. Three types of glycosylation exist: N-(glycans linked to an Asn of an Asn-X-
Ser, Asn-X-Thr, or Asn-X-Cys consensus sequence, where X is any amino acid except proline), O-
(glycans linked to a Ser or Thr), and C (attached to a Tryptophan) linked 128. Of these, N-linked 
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glycosylation is the most studied and is considered as the most relevant for recombinant protein 
production. Glycosylation profiles are protein-, tissue-, and animal-specific 186; moreover, different 
glycosylation sites are often glycosylated in different ways 186. Recombinant proteins may therefore 
present macroheterogeneous (differences in site occupancy) or microheterogeneous (differences in 
the structures of oligosaccharides between glycosylation sites) glycosylation 187, but nonauthentic 
glycosylation may trigger immune responses when present in proteins for human or animal use 188. 
Accordingly, authentic glycosylation pattern is especially relevant for recombinant proteins to be 
utilized as drugs, but, given the complexity of the process, several bottlenecks are present. 
For example, Dolichol-Phosphate is a molecule that functions as a membrane anchor for the 
formation of the oligosaccharides that will be transferred from the Dolichol donor to Asn residues  
of newly forming polypeptide chains187; So the synthesis of the dolichol-phosphate oligosaccharide 
can limit the extent of glycosylation. As an attempt to solve this, Dolichol-Phosphate has been fed 
to CHO cells producing recombinant proteins, but, although it was internalized, no increase in 
glycosylation site occupancy was observed188. Also sugar nucleotides, required for oligosaccharide 
synthesis, can limit the build-up of the polysaccharide precursors and reduce the glycosylation site 
occupancy189. Limitation of sugar nucleotide donors can occur upon prolonged glucose or 
glutamine starvation189; in order to alleviate such a problem, sugar nucleotide precursors are added 
to the culture medium190. Even the transport of sugar nucleotides to the ER and Golgi apparatus 
can affect glycosylation190.  
Moreover, protein glycosylation is a dynamic phenomenon that changes as culture time 
progresses191; glycosylation levels it has been demonstrated to increase with increasing culture time 
until the onset of cell death188.  
• Other Posttranslational Modifications 
Other posttranslational modifications, such as myristoylation, palmitoylation, isoprenylation, 
phosphorylation, sulfation, C-terminal amidation, ββ-hydroxylation, and methylation, are less 
common than glycosylation, but may be important for certain recombinant proteins192. In general, 
the extent of modification depends on the host utilized, being the modifications performed by 
higher eukaryotic cells closer to those found in human proteins. 
iii. Transport and Localization 
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Recombinant proteins may be directed to different cellular compartments by signal peptides or 
through fusion proteins, and it is very important that characteristics of the protein were carefully 
considered when deciding the site of accumulation. For example, small proteins susceptible to 
proteolysis should be produced in bacteria as inclusion bodies. Apart from intra- or extracellular 
accumulation, certain applications may require recombinant proteins to be targeted to a specific 
compartment, like the cell membrane or the ER, through fusion proteins or by the addition of 
aminoacidic motif like the KDEL one193. The transport efficiency of the protein of interest 
depends on the signal peptide utilized, which should be chosen according to the host; indeed 
nonoptimal selection of the signal peptide may result in intracellular protein accumulation and 
aggregation. In some cases, in bacteria expression system, the accumulation of recombinant 
proteins in the periplasm often results in soluble and correctly folded proteins, whereas cytoplasmic 
localization yields an inactive and insoluble product194. 
1.3.2 Overview of Current Expression System 
As said before, efficient strategies for the production of recombinant proteins are gaining increasing 
importance, as more applications that require high amounts of high-quality proteins reach the 
market. Higher production efficiencies and, consequently, lower costs of the final product are 
needed for obtaining a commercially viable process. Given size and complexity of proteins, 
chemical synthesis is not a viable option for this attempt; instead, living cells, like bacteria, yeast, or 
mammalian cells, with their cellular machinery are usually harnessed as factories to build and 
construct proteins based on supplied genetic templates. Indeed, unlike proteins, DNA is simple to 
construct and manipulate using well established recombinant DNA techniques; thus, DNA 
templates of specific genes, with or without add-on reporter or affinity tag sequences, can be 
constructed as templates for protein expression 157. 
Traditional strategies for recombinant protein expression involve transfecting cells with a DNA 
vector that contains the template and then culturing the cells so that they transcribe and translate 
the desired protein. Typically, the cells are then lysed in order to extract the expressed protein for 
purification. Both prokaryotic and eukaryotic in vivo protein expression systems are widely used 
and the selection of a system might depend on the type of protein, the requirements for functional 
activity and the desired yield. 
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Nowadays biopharmaceutical products are currently made using micro-organisms195, animal cell 
lines 196, plants197 or animals198 (see the resume in Table 3). Plants, particularly, have been proposed 
as an attractive alternative for pharmaceutical protein production to current mammalian or 
microbial cell-based systems. Eukaryotic protein processing coupled with reduced production costs 
and low risk for mammalian pathogen contamination and other impurities have led many to predict 
that agricultural systems may offer the next wave for pharmaceuticals production199. 
i. Cell-free Protein Expression 
Cell-free protein expression is the in vitro synthesis of protein using translation-compatible extracts 
of whole cells. In principle, whole cell extracts contain all the macromolecules components needed 
for transcription, translation and even post-translational modification, these components include 
RNA polymerase, regulatory protein factors, transcription factors, ribosomes, and tRNA. When 
supplemented with cofactors, nucleotides and the specific gene template, these extracts can 
synthesize proteins of interest in a few hours. 
However this system is not sustainable for large scale production. Although the low yield of 
product, cell-free protein expression systems have some advantages over traditional in vivo systems, 
like enabling protein labelling with modified amino acids, as well as expression of proteins that 
undergo rapid proteolytic degradation by intracellular proteases 200. Also, with the cell-free method, 
it is simpler to express many different proteins simultaneously 200. 
 
Table 3: Overview of most common cellular expression systems and their main characteristics. 
System 
Overall 
Cost 
Production 
Timescale 
Scale-up 
Capacity 
Product 
Quality 
Glycosylation 
Contamination 
Risks 
Bacteria Low Short High Low None Endotoxins 
Yeast Medium Medium High Medium Not Correct Low Risk 
Mammalian 
Cell Culture 
High Long Low Very High Correct Viruses, prions 
Transgenic 
Animals 
High Very Long Low Very High Correct Viruses, prions 
Transgenic 
Plants 
Very 
Low 
Long High High 
Minor 
Differences 
Low Risk 
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ii. Bacterial Expression System 
Bacterial protein expression systems are popular because they are inexpensive, offer rapid culture 
times and may to achieve high biomass and high protein yields 201. Today, one third of FDA 
approved protein therapeutics are produced in Escherichia coli, (E. coli) indicating that it is a major 
workhorse for recombinant therapeutic production 202.The Gram-negative bacterium E. coli was the 
first organism utilized for the production of recombinant human proteins, and is the most 
attractive because of its well-characterized genetics, versatile cloning tools and expression systems, 
and the fact that it has been successfully used to express vastly different proteins. It is also 
advantageous to use E. coli for industrial scale production because of its rapid growth, low-cost 
media, ease of scale-up and capability to produce therapeutics with high yield and quality 202. 
However, despite these advantages there are also several limitations to using E. coli as an expression 
host; among the most constraining ones there are the inability to perform certain posttranslational 
modifications (such as glycosylation) and insufficiencies in proteolytic protein maturation and 
disulfide bond formation 203. Such drawbacks prohibit E. coli from expressing some complex 
therapeutics, such as monoclonal antibodies (mAbs), where both correct folding and glycosylation 
play crucial roles in their biological activities. Also, as discussed in previous section, in E. coli, like 
in other bacteria, many proteins become insoluble as inclusion bodies that are very difficult to 
recover without harsh denaturants and subsequent protein-refolding procedures, and there is a 
problem of variability in the level of expression 159,173. Another concern about the expression of 
recombinant proteins in bacteria include pyrogens and endotoxins, that must be totally eliminated 
from proteins to be injected in animals or humans. Despite all this drawbacks, in some specific 
conditions, like the case of a protein not requiring any of these modifications for obtaining an 
adequate product, bacteria can be host of choice 201.  
Gram-positive bacteria have also been utilized for recombinant protein production, with the 
advantage that they can secrete large amounts of properly folded product and that contain lower 
concentrations of pyrogens 204. Nowadays, Bacillus subtilis (B. subtilis) is generally recognized as safe 
and can be used for the production of proteins for the food industry 205; however, recombinant 
plasmids are not stable in this system, so chromosomal integration is the only way to obtain a stable 
recombinant cell. Moreover, due to the high activity of endogenous proteases, yields are lower than 
those of Gram-negative bacteria 201. 
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iii. Mammalian Expression System 
Although animal cell cultures have been important at a laboratory scale for most of the last 100 
years, it was the initial need for human viral vaccines (e.g. for poliomyelitis) in the 1950s that 
accelerated the design of large-scale bioprocesses for mammalian cells, but their complexity delayed 
their genetic manipulation to the time when manipulation of bacterial genomes was performed 
almost routinely 207. Mammalian in vivo expression systems usually produce functional protein 
because of their proper protein folding, assembly, and post-translational modification, but the yield 
is low, cost of production is high and mammalian cell culturing is time-consuming 207. In addition, 
subtle differences exist between glycans obtained in commonly used mammalian cell lines and those 
associated with glycoproteins synthesized in human cells 208. For example, cell lines like CHO lack 
a α2,6-sialyltransferase enzyme, which exists in human cells; however, recently, cloning glycosyl-
transferases into common mammalian cell lines has proved useful for the expression of humanized 
N-glycoproteins and O-glycoproteins 209. Moreover, successful recombinant protein production in 
animal cells had to overcome many hurdles, such as the cellular fragility and the complex 
nutritional requirements of cells 157. Animal cells require hormones and growth factors that were 
initially supplied by bovine serum, but possible contamination of the final product with virus or 
prions, and the difficulty of recovering extracellular proteins from serum-containing media, have 
resulted in the development of serum-free media that are used for large-scale production 210. 
The development of mammalian cell culture methodologies included designing a variety of vector 
systems and of gene transfer methods 211; a recent development in gene transfer is the use of 
Baculovirus vectors, that carry promoters that are efficiently transcribed in cultured mammalian 
cells.  
Other issues that arise when expressing proteins in mammalian cells can be solved through cell 
engineering. For example, when large scale production is engaged, the cells suffer metabolic 
pressures, such as oxygen depletion and toxic metabolite accumulation, which affect final yields. 
Traditional strategies for productivity optimization involve manipulation of cell division as well as 
cell longevity, supported by the increasing knowledge of cell cycle control 212. An interesting 
approach with CHO cells consisted of engineering their mRNA translation initiation machinery 
with the aim of leaving it on, despite stressful conditions derived from large-scale production 213.  
Recently, the productivity of mammalian cells cultivated in bioreactors has reached high yield in 
recombinant protein production, which mainly resulted from improvements of cell line 
development through effective selection methods, media optimization, and process control. 
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Currently, more than 50% of therapeutic proteins approved and on the market are produced using 
mammalian cells 172,207. 
iv. Other Cell Expression System 
The yeast Saccharomyces cerevisiae  (S. cerevisiae ) was the first yeast species to be manipulated for 
recombinant protein expression, and many proteins have been produced in it 214. S. cerevisiae grows 
rapidly in a relatively simple medium to high densities with a high level of product secretion and it 
also demonstrates a eukaryotic subcellular organization capable of some posttranslational 
modifications. Moreover, this yeast produces a reasonable amount of recombinant proteins and it 
also secretes the proteins outside the cell envelope, which reduces the cost of downstream 
processing215. However, because this yeast lacks the amylolytic activity necessary for starch 
utilization, the genes encoding Glucoamylase (GA) were cloned into this organism in order to 
extend its substrate utilization range and S. cerevisiae has been used as a host organism for the 
production of several recombinant proteins 216. 
As other eukaryotes, yeasts are also capable of performing some posttranslational processing typical 
of mammalian cells; however, extracellular proteases and differences in glycosylation of proteins 
expressed in yeast compared to those of mammalian cells, limit their use. N-glycosylation of 
proteins produced by yeasts are high-mannose (with more than 3 mannose residues) or hyper-
mannose (more than 6 mannose residues) types, with terminal α-1,3 linkages, and these forms are 
very immunogenic to mammals 217. Even if cell engineering has been utilized for obtaining non-
immunogenic glycoproteins from yeasts 218, unmodified yeasts are still suitable for the production of 
proteins that do not require mammalian-type glycosylation and are resistant to proteases. One of 
these proteins is insulin, which has been commercially produced in S. Cerevisiae after enhancing its 
folding and secretion capacities through genetic engineering 214. Other yeasts, such as Pichia 
pastoris, and Candida boidinii, are hosts with various recombinant proteins, like the hepatitis B 
vaccine, human serum Albumin and insulin-like growth factor, within reach or already in the 
market 219. 
Filamentous fungi have been utilized for the production of a variety of substances with various 
applications because of their ability of secrete large amounts of homologous and heterologous 
proteins 220. Furthermore, recombinant protein concentration can be increased by fusing the gene of 
interest with genes of fungal origin 220. A limitation for fungi utility for recombinant protein 
production is the presence of protease, even if promoting growth in pellets and controlling pH can 
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reduce their activity 221. Furthermore, as in yeasts, filamentous fungi produce high-mannose-type 
glycans, easily recognized by mammalian lectins; therefore, recombinant proteins intended for 
therapeutic use and expressed in fungi can be rapidly and inconveniently cleared from blood 222. 
v. Transgenic Animals 
The potential of using transgenic animals as bioreactors for production of complex and high-value 
proteins has been explored in recent years. Produce recombinant proteins in a transgenic animal 
system can be advantageous because of its ability to process highly modified proteins 223. This 
system is also flexible: processing enzymes can be co-expressed with foreign products to obtain 
more recombinant proteins. The first transgenic livestock were produced in 1985 by microinjection 
of foreign DNA into zygotic pronuclei; this was the method of choice for more than 20 years, but 
more efficient protocols, including somatic cell nuclear transfer and lentiviral transgenesis, are 
available nowadays 224. In last years, transgenic farm animal production for biomedical applications 
has found broad acceptance; the European Medicines Agency in 2006 approved the 
commercialization of the first recombinant pharmaceutical protein, Antithrombin, produced in the 
mammary gland of transgenic goats 225. 
The production of recombinant pharmaceutically active human proteins in the mammary gland or 
blood of transgenic animals has advanced to the stage of commercial application 226; mammary 
gland is the preferred production site mainly because it lactates a large quantity of protein in milk 
on a daily basis and because there are established methods for extraction and purification of the 
respective protein 223. Guidelines developed by the FDA require, beside sequence validation of the 
gene construct and characterization of the isolated recombinant protein, also a strict monitoring of 
animals health in a specific pathogen free facility, in order to avoid the possibility of disease 
transmission from animal to human, that is one of major concern with transgenic animals 227 
Several products, including monoclonal antibodies derived from the mammary glands of transgenic 
goats, sheep and rabbits have progressed to advanced clinical trials 225. An interesting new 
development is the generation of trans-chromosomal animals carrying the complete sequence of the 
human immunoglobulin heavy and light chain loci on a human artificial chromosome (HAC); 
trans-chromosomal bovine clones expressed human immunoglobulin in their blood 228. This system 
is a significant step forward in the production of therapeutic human polyclonal antibodies 228. 
Recently, the possibility to use transgenic chickens as bioreactors in order to synthesise therapeutic 
proteins as a component of egg yolk or white, has been investigated; the use of these animals may 
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have several advantages over mammalian expression systems, including a shorter timescale for setup 
and ease of scale-up to a transgenic flock, lower costs associated with husbandry, the potential to 
produce proteins that are toxic to mammalian cells, beneficial glycosylation profile, and reduced 
immunogenicity of the purified product 229. 
vi. Transgenic Plants 
Starting from the end of ‘90s, many studies have shown that recombinant proteins production in 
plants has many practical, economic and safety advantages compared with more conventional 
systems, and so the use of plants for large-scale protein synthesis have started gaining wider 
acceptance 230,231. Plant cells, as eukaryotic systems, possess the features to produce biologically 
active therapeutic proteins; indeed, different kind of proteins, such as enzymes (i.e. trypsin and 
lysozyme), monoclonal antibodies (i.e. IgA, IgG and IgM) and antigens for edible vaccines are 
currently produced in plants 232. Soybean, tobacco and rice, are nowadays the most commonly used 
plants for transgenic protein production 230. 
Transgenic plants are relatively cheap to grow on a large scale; there are established practices for 
effective harvesting, transporting, storing and processing of plants; other potential advantage of this 
system is the elimination of purification process when the plant tissue containing recombinant 
proteins can be used as food and the possibility that recombinant protein can be produced and 
accumulated in different organelles 231. For example, recombinant proteins can accumulate in seeds, 
which can be harvested in dry state and then can be stored without concern of protein degradation 
232. Recombinant proteins can be also directed in a specific compartment of the cells in order to 
increase the level of final product, that can otherwise result insufficient without any kind of 
accumulation strategy. As a matter of fact, subcellular targeting is one of the most important factors 
governing the yield of recombinant proteins, but it is important to remember that the targeting 
affects also the interlinked processes of folding, assembly and post-translational modification 230. 
1.4 Recombinant BMP-2 Production for Pharmaceutical 
Purpose 
Since bone contain very low amounts of native BMPs, all methods to extract and purify biologically 
active BMPs from it are time-consuming, labour intensive, and most importantly, result in a very 
low yield 233,234; for instance, beginning with kilogram quantities of bone, microgram quantities of 
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purified osteoinductive material eventually were obtained, and biochemical analysis indicated that 
despite the extensive purification, multiple proteins still were present 25,28. Even more, the potential 
health risk associated with their isolation from allogeneic donor bone limits their clinical 
application 235. For these reasons, when at the end of the 1980s the coding sequences for BMP 
family members were first cloned and expressed, recombinant human BMP-2 has started to be 
obtained from cellular expression systems, opening the possibilities for therapeutic application 29. 
Over the ‘90s, several attempts to express active BMPs in different cellular systems (such as E. coli, 
P. pastoris, Baculovirus/insect cells, and mammalian cells) have been made 236, but, because of 
problems of glycosylation and folding that occur during the production of rhBMP-2 in bacteria 
and virus infected insect cells 237,238, none of these products reached the market. As a matter of fact, 
for therapeutic purposes it is necessary to express BMP-2 in large-scale and in a system that ensures 
correct folding, biological activity, and no immunogenicity, imposing the use of eukaryotic 
expression systems. One major advantage of recombinant expression of proteins in mammalian 
cells is that the yield is higher than that produced in the native cells because the level of gene 
expression in native cells is tightly controlled; conversely, recombinant DNA technology allows 
strategies to circumvent the natural control of the cells, hence increasing the level of protein 
production.  
For all these reasons, it was only in 2001 that first FDA approved rhBMP obtained from CHO cell 
lines, reached the market 36,37. Nowadays rhBMP-2 and rhBMP-7, successfully produced as active 
protein, have been shown to undergo proper post-translational modifications, are proteolytically 
processed from their precursor, and most importantly, have been shown to be biologically active, 
stimulating  osteoblastic maturation in vitro and inducing bone formation in vivo 35,72. 
These two BMPs are still the only ones to be approved and commercialized, even if recently, 
several papers describe the attempt of production of biologically active rhBMP-2 through in vitro 
refolding of engineered Escherichia coli produced inclusion bodies, with biological activity expected 
to be equivalent to CHO produced rhBMP-2 238. However, a disadvantage of these procedures is 
the requirement of several time-consuming purification and concentration steps before the 
refolding attempt 239, and the study of these products is still on a preclinical stage 240,241 
1.4.1  Recombinant BMP-2 Production in CHO Cell Line 
Chinese Hamster Ovarian cell line has become the standard choice of mammalian host cells in 
recombinant protein production 201,242. This cell line has been well characterized, allowing for 
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transfection, gene amplification, and selection of high-end clones. Even if non-human cells might 
produce proteins improperly glycosylated compared to human cell lines, the major concern with 
using human cell line for recombinant protein production is the possibility that pathogens infecting 
human host cells being present in the recombinant protein and thus being transmitted to patients; 
the chance of disease transmission from non-human cell line-produced recombinant proteins is 
lower than that from proteins produced by human cells since the disease spread easier in the same 
species 243.  
To establish a cell line, the cDNA encoding BMP-2 protein is inserted into a plasmid with a 
strong promoter, which drives the expression of the recombinant gene, then this plasmid is 
transfected into host cells 244. Non-viral gene transfer methods including calcium phosphate 
transfection, electroporation, lipofection and polymer-mediated gene transfer, are preferred 
methods for manufacturing and regulatory purposes 243. In addition to the recombinant gene, a 
second gene is incorporated into the plasmid, to give host cells a selective advantage, ensuring that 
only those cells that express the selector gene survive. Following selection, survivors are transferred 
as single cells to a second cultivation vessel, and the cultures are expanded to produce a clonal 
population; individual clones are then evaluated for recombinant protein expression, with the 
highest producers being retained for further cultivation and analysis 245. From these candidates, one 
cell line with the appropriate growth and productivity is chosen for production of recombinant 
protein and expanded in order to obtain an homogeneous population of  cells capable of producing 
the correct recombinant protein at high level. Then, from a single batch of rhBMP-2 production, 
the cells are grown and distributed into several small vials, forming a “cell bank”, that is a source for 
all future production. 
To promote faster cellular replication and production of rhBMP-2, the cells are transferred to a 
bioreactor, a computer-controlled, closed-system environment where large-scale production of the 
protein begins. After a growth period of about three days, the cells are filtered away from the 
rhBMP-2 containing medium and discarded; the rhBMP-2 moves on to the purification process, 
that involves a series of four chromatography columns, a virus-retaining filtration step, an 
ultrafiltration step and a further final nanofiltration step. All these steps are performed in order to 
assess the total viral safety of the product, even though no human or animal components are added 
during the recombinant production process. Throughout the production process, quality control 
testing is done to assess the safety, consistency and purity of all materials by a large number of tests 
that are completed during the manufacture of rhBMP-2. In addition, viral and microbial agent 
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evaluations were conducted in accordance with guidance document regarding viral safety evaluation 
of human and animal cell lines. 
i. Productivity and Efficiency of this Production System 
The productivity of recombinant cell lines has increased in the past 20 years. In the 1980s, 
mammalian cells typically reached a density of about 2 x 106 cells/ml with a batch process 
production phase of about a week and a specific productivity slightly below 10 pg/cell/day 243; 
during the same process performed in 2004, the culture was started at a low cell density of about 
100,000 cells/ml and rapidly grew into a density of more than 10 x 106 cells/ml; a high level of cell 
viability was maintained for almost 3 weeks with a specific productivity up to approximately 90 
pg/cell/day 243. As explained in previous sections, this higher yield obtained in today’s processes is 
the result of years of research that led to a better understanding of gene expression, metabolism, 
growth and apoptosis in mammalian cells. Overall efforts have led to improvements in vectors, host 
cell engineering, medium development, screening methods, and process engineering and 
development. 
Despite the success of producing active rhBMP-2, the main challenge of a mammalian expression 
system is its yield, which has been reported to be lower than other systems, in a µg/L range 35. 
From the pioneering work of Israel, assuming a yield of 30 µg/L and a cell density of 106 cell/, the 
specific productivity is merely 0.03 pg/cell/day after a 24-hr production period, while recombinant 
antibodies produced by CHO cells the same cell density in a batch system for 3 weeks had a 
specific productivity of 90 pg/cell/day 243. Comparing with the specific productivities, the rhBMP-2 
production results lower than that of other recombinant products, although considering that the 
rhBMP-2 was, in 1992, produced in a lab scale setup whereas the recombinant antibodies were 
produced on an industrial scale, with an optimized manufacturing process.  
Efforts made to improve rhBMP-2 productivity in mammalian cell systems were suggested and 
introduced; they can be divided into two areas. The first involves increasing or maintaining 
transcription of the transgenes by methods such as improving vector design, plasmid integration 
and optimizing the chromosomal environment. The second works on maximizing the translational 
or secretory capacity of the host cells through methods such as host cell engineering, media 
optimization, and improved bioreactor design and feeding 246.  
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Although all correct post-translational modifications in rhBMP-2 production can be obtained by 
the co-expression of soluble exogenous enzyme in CHO cells, the issue of low productivity has not 
been totally resolved 247. 
1.5 Rationale of Using Plants for Producing rhBMPs 
As told before, despite initial industry conservatism, plants have emerged as one of the most 
promising general production platforms for biologics, and transgenic plants are nowadays accepted 
as a safe, effective and affordable system to produce recombinant proteins for medical purposes, 
including mammalian antibodies, blood substitutes, vaccines and growth factors 248. Plants allow 
the cost-effective production of recombinant proteins on an agricultural scale, while eliminating 
risks of product contamination with endotoxins or human pathogens 249.  
Main limitations encountered during plant production systems development include the low yields 
achieved for some proteins, often caused by poor protein stability, and the difficulties with 
downstream processing that lead to insufficient product quality 250; nevertheless, many technical 
advances achieved over the past years have helped to address these limitations, thus making the 
prospect of affordable, plant-derived biologics possible 249. 
Tobacco plants are the system of choice in which many of the early plant-derived recombinant 
proteins were produced and extracted, mainly directly from harvested leaves. Tobacco is considered 
a well-established expression host, with strong transformation procedures available and well-
characterized regulatory elements for the control of transgene expression 251. Moreover, high 
biomass yields and rapid scalability make tobacco a very suitable host for commercial molecular 
farming, and it is also a non-food, non-feed crop, carrying a reduced risk of transgenic material or 
recombinant proteins contaminating feed and human food chains 249, even if it should be 
considered that it has an high content of nicotine and other toxic alkaloids, which must be removed 
completely during downstream processing steps 249. Tobacco has been already adopted as a platform 
system by several biotech companies that have plant-derived pharmaceuticals undergoing clinical 
trials, including “Planet Biotechnology Inc.” and “Meristem Therapeutics”. 
Knowing the variability of recombinant protein yield obtained from tobacco plant, a strategy that 
allows to obtain the greater quantity (and quality) of the product is required. As a matter of fact, 
the level of accumulation of a recombinant protein in transgenic plants is protein specific and 
strongly influenced by the subcellular compartment of destination 231; thus, search for the best 
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subcellular compartment for targeting the protein of interest represents a major issue in the effort 
to maximize production 252.  
The subcellular compartments influence levels of accumulation of proteins, mainly for two reasons 
231. Former, the subcellular environment affect the folding of proteins: the more similar the 
environment to the native location is, the more probably the protein will be able to acquire the 
native conformation. Latter, the proteolysis of the protein by host proteases, that occur in the 
cytoplasm, and the interferences with host molecular function may lead to production drawbacks. 
As mentioned in chapter 1.2, ER is a compartment of transit for secretory proteins; it allows the 
entry into the secretory pathway of newly synthesized proteins and ensures their correct folding, 
moreover this compartment demonstrated to possess a very low hydrolytic activity and to be very 
plastic (Figure 6) 253. When abnormal proteins accumulation in the ER occurs in mammalian cells, 
it results in large aggregates that in the long term are detrimental and toxic to cellular functions, 
causing pathologic conditions 254. Conversely, the ER of plant cells can tolerate high accumulation 
 
Figure 6: The secretory pathways of plant cells versus animal cells. Secretory proteins enter the ER (delimited here by 
the broken line) in both cell types and travel to the Golgi complex via vesicular trafficking. In the absence of ER-
retention signals, soluble proteins are then secreted (blue arrows). Vesicular sorting to the inner hydrolytic 
compartments (lytic vacuoles in plants, lysosomes in animals; green arrows) requires signals that differ in plants and 
animals. In addition to lytic vacuoles, plant cells may also have protein storage vacuoles (PSV), which develop 
according to specific signals and protein sorting mechanisms (orange arrow). Vast amounts of proteins of cereals (e.g., 
the prolamin storage proteins) form protein bodies (PB) within the ER in aggregation processes that may be useful in 
the biotechnological production of recombinant pharmaceutical proteins. 
Figure taken from Vitale & Pedrazzini, Molecular Interventions 2005. 
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Most important, when the N-terminal fragment, that includes the eight Prolin-rich repeats and the 
first six Cystein residues, was fused to the C-terminus of phaseolin, a vacuolar storage globulin of 
common bean, the chimeric construct forms polymers having the main features of γ-zein: 
insolubility unless reduction and accumulation as PB in the ER 258. Collectively, these data indicate 
that the N-terminal region of γ-zein forms inter-chain disulfide bonds and contains information 
sufficient for ER retention, independent of any specific machinery. Consequently, a fusion protein-
based system designed to accumulate recombinant proteins in ER-derived PBs in plant was 
developed: the approach is based on fusion proteins that contain aminoacids 1–112 of γ-zein 
sequence, named Zera® sequence (developed by ERA Biotech, Barcelona, Spain) fused to the 
protein of interest 267,268. The formation γ-zein-induced protein bodies and an enhanced 
recombinant proteins accumulation were confirmed both in vegetative tissue and in non plant 
eukaryotic systems (fungal, insect and mammalian cells) 267,268; PB formation enables high local 
concentrations of heterologous proteins to exist within the limited space of the cell, while 
preserving the protein from normal cellular protein degradation mechanisms, and without 
subjecting the ER to an intolerable level of stress 252,269. 
These results demonstrate that this portion of γ-zein sequences can be used as an alternative to the 
KDEL signal when accumulation of recombinant proteins in the ER is useful for their production 
and recovery 270. 
1.6 Objectives 
In an effort to obtain cost-effective production of functional rhBMP2, the purpose of this study is 
to explore tobacco plants as bioreactors. 
Thus, in order to increase the accumulation of rhBMP-2 in these plants, a fusion-protein (named 
ER-BMP2) between the C-terminal active peptide of human BMP2 and the N-terminal domain 
of maize γ -zein was obtained. The accumulation level of ER-BMP2 was then compared with that 
of the native form of human BMP-2 (N-BMP2). 
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2 Materials and Methods 
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2.1 Plant Material 
2.1.1 Protoplasts Isolation from Leaf Tissue 
Protoplasts were isolated from tobacco leaves and subjected to polyethylene glycol-mediated 
transfection, as described by Pedrazzini et al. (1997) 271.  
Briefly, leaves of 3-5 weeks old from axenic Nicotiana Tabacum (L. var. Petit Havana SR1) plants 
were cut underside every 1-2mm and laid down overnight on a digestion enzyme solution, which 
consisted of a combination of 0,17% (w/v) macerozyme and 0,33% (w/v) cellulase prepared in K3 
medium (Gamborg’s B5 basal media with minimal organics (Duchefa Biochemie) supplemented 
with 400mM sucrose, 1,5M xylose, 3mM NH4NO3, 1 mg/l α-naphtalenacetic acid (NAA), 1 
mg/l 6-benzylaminopurine (BAP) and 5mM CaCl2). Protoplasts were filtered through a 85µm 
filter and washed twice with W5 buffer (154mM NaCl, 125mM CaCl2, 5mM KCl, 5mM 
Glucose) by adding 4 volumes of buffer, resuspending the protoplasts and centrifuging at 60g for 
10 min (brake off). Protoplasts were then resuspended in 10ml of W5 and incubated 30 min in the 
dark. An aliquot of protoplasts preparation was diluted 10 times in K3 buffer containing 10 µg/ml 
fluorescein diacetate (FDA) and 1µl of this diluted preparation was observed at microscope to 
count fluorescent cells. After a new centrifugation (60g for 10 min) protoplasts were resuspended at 
a concentration of 106 cell/ml in K3 medium. 
2.1.2 Protoplast Transformation 
The protoplasts, isolated as described in the previous section, were centrifuged at 60g for 10 min 
(brake off) and resuspended in MaCa buffer (0.5mM mannitol, 20mM CaCl2 and 0.1% MES pH 
5.7) at a concentration of 106 cell/ml. After heat shock (5 min at 45°C) 40 µg of pDHA or pGreen 
plasmid without insert (as a negative control) or with inserted recombinant coding sequences were 
used in each transfection at a concentration of 106 cells/ml. Equal volume of 40% PEG solution 
(0,4M mannitol, 0,1M Ca(NO3)2, 40% (w/v) PEG) was added dropwise. After 30 min of 
incubation at room temperature, protoplasts were washed with 10 ml of W5 buffer, resuspended in 
1ml of K3 buffer. Protoplasts were then allowed to recover overnight in the dark at 25 °C in K3 
medium before performing protein extraction. 
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2.1.3 Wild-Type and Transgenic Plants 
Wild-type or transgenic tobacco plants (Nicotiana Tabacum L. var. Petit Havana SR1) were grown 
in sterile conditions on half-concentrated Murashige and Skoog Basal Medium (½MS, Duchefa 
Biochemie) supplemented with 10g/l sucrose and 0,8% (w/v) phyto agar (Duchefa Biochemie) at 
25°C under 16/8h light/dark cycle. 
Transgenic Tobacco plants expressing ER-BMP2 and N-BMP2 were generated by Agrobacterium-
mediated transformation of plant tissues (leaf-disk). The plants were transformed with 
Agrobacterium tumefaciens  strain GV3101 harbouring binary vectors containing expression cassettes 
with the sequences of the Cauliflower Mosaic Virus (CaMV) S35 promoter and the sequences of 
the proteins of interest. 
Fully expanded tobacco leaves were excised from axenically grown wild-type plants and cut with 
sterile tools into 1 cm2 leaf discs. The explants were submerged for 10 min in a suspension of A. 
tumefaciens carrying the plasmid of interest, and then blotted on to sterile filter paper to remove the 
excess Agrobacterium culture. Leaf discs were incubated underside down at 25 °C in the dark on 
shoot-inducing medium (SIM) agar (MS salts containing 30 g/l sucrose and 0.8% phyto agar 
(Duchefa Biochemie)). After 2 days the leaf discs were transferred to shooter generation medium  
(SGM) (½MS salts supplemented with 30 g/l sucrose, 0,1 mg/l NAA, 1 mg/l BAP, 50 µg/ml 
hygromycin, 100 µg/ml carbenicillin and 250 µg/ml cefotaxime) in order to promote callus growth, 
select transformed plants and to prevent further growth of Agrobacterium. Leaf discs were 
transferred to new media at least every 2 weeks until the growth of calli. When calli were present 
they were excised and placed on new plates to promote shoots formation. Elongated shoots were 
excised from calli and transferred on ½MS supplemented with 30 g/l sucrose, 0,1 mg/l indole-3-
acetic acid (IAA), 50 µg/ml hygromycin and 100 µg/ml carbenicillin to promote lateral root 
formation. 
After 2 – 3 weeks, regenerated plants were tested for recombinant protein expression and then 
grown in soil. 
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2.2 Protein Methods 
2.2.1 Protein Extraction from Protoplasts and Plant Tissue 
i. Protoplasts 
Frozen samples of protoplasts were homogenised with 2 volumes of ice-cold 1,5X protoplasts 
homogenisation buffer (150 mM NaCl, 1,5 mM EDTA, 1,5% (v/v) Triton X-100, 150 mM Tris-
Cl pH 7.5) supplemented with Complete protease inhibitors (Roche) in presence or absence of 
reducing agent (4% (v/v) 2-mercaptoethanol (2-ME). 
Homogenization of protoplasts incubation medium was performed similarly using homogenization 
buffer supplemented or not with 2-ME. 
The homogenates were then centrifuged at 1500g for 10 min at 4°C and supernatants and pellets 
were adjusted for SDS-PAGE. 
ii. Tobacco Leaves 
For total protein extraction from plant tissues, Tobacco leaves were homogenised in ice-cold 
homogenisation buffer (100mM Tris-Cl pH 7.8, 200mM NaCl, 1mM EDTA, 0,2% (v/v) Triton 
X-100, supplemented with Complete (Roche)) in presence or absence of 4% (v/v) 2-ME. Ratio 
volume of buffer/weight of the leaves was 5-7/1. 
The homogenates were then centrifuged at 1500g for 10 min at 4°C and supernatants and pellets 
were adjusted for SDS-PAGE experiments. 
iii. Tobacco Seeds 
For total protein extraction from Tobacco seeds, 0.05g of such tissue were homogenised in SDS-
PAGE loading buffer (20mM Tris-Cl pH 8.6, 1% (w/v) SDS, 10% (v/v) glycerol, 0,17% (w/v) 
bromophenol blue and 4% (v/v) 2-ME) at 95°C. the volume of buffer/weight of the seeds ratio was 
10/1. 
The homogenates were then centrifuged at 14000g for 5 min at 4°C. Supernatants were then 
collected by paying care to avoiding the upper oil phase and 5µl were analyzed with SDS-PAGE. 
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2.2.2 Protein Quantification 
Total proteins were quantified using the Bradford protein assays 272. Briefly, 1 to 10µl of protein 
samples were mixed with Bradford Reagent (Sigma) up to 1 ml volume; after an incubation of 15 
min at room temperature (RT) , absorbance was read at 595 nm. A standard curve was obtained 
with Bovine Serum Albumin (BSA, Sigma) solution (from 0 to 1000 µg/ml) in Bradford Reagent. 
2.2.3 Protein Extraction for Transgenic Tobacco Plant Screening 
Tobacco leaves were homogenised in SDS-PAGE loading (denaturing) buffer (20mM Tris-Cl pH 
8.6, 1% (w/v) SDS, 10% (v/v) glycerol, 0,17% (w/v) bromophenol blue and 4% (v/v) 2-ME) at 
95°C. The volume of buffer/weight of the leaves ratio was 5/1. 
The homogenates were then centrifuged at 1500g for 10 min at 4°C and the supernatants were 
collected, diluted 1/10 in loading buffer and analyzed with SDS-PAGE and protein blot (used for 
the screening of F0 positive plants) or directly spotted (5µl) on Protran nitrocellulose membrane 
(Perkin Elmer) for direct immunodecoration (used for screening of positive F1 plants). 
2.2.4 Endoglycosidase H Treatment 
For Endoglycosidase H (Endo H, New England BioLabs) treatment, protein samples were 
incubated with 10x Glycoprotein Denaturing Buffer (0,5% (w/v) SDS, 40mM DTT (New 
England Biolabs, Beverly, MA, USA)) for 10 min at 100°C. Samples were brought to a volume of 
at least 20µl by adding of 10x G5 Reaction Buffer (50mM sodium citrate pH 5.5) and divided in 
two equal aliquots. One of them was treated with 2,000 Units of Endo H enzyme (New England 
Biolabs), the other one with an equal volume of water. After 2 hours incubation at 37°C the 
samples were supplemented with Laemmli denaturation buffer and analyzed by either SDS-PAGE 
and protein blotting. 
2.2.5 Thrombin Cleavage 
About 20µg of total protein extracts from transgenic and control plants in reducing condition were 
incubated with 10 units of thrombin or with same quantity of PBS (as control) at 22°C for 20 h 
under gentle agitation. After digestion, to verify the occurrence and extent of thrombin digestion, 
samples were analysed by SDS-PAGE and protein blot with anti-FLAG antiserum. 
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2.2.6 Velocity Centrifugation on Sucrose Gradient 
Tobacco leaves or protoplasts were homogenised in ice cold homogenisation buffer in non-
reducing conditions; homogenate was centrifuged at 1500g for 10 min at 4°C and supernatant was 
recovered. Extracted proteins were layered on a 11.5 ml linear 5-25% (w/v) sucrose gradient made 
in 150mM NaCl, 1mM EDTA, 0,1% (v/v) Triton X-100, 50mM Tris-Cl pH 7.5. An additional 
gradient was loaded with a mixture of markers containing 200µg each of cytochrome C (12.4 kDa), 
ovalbumin (43 kDa), BSA (66 kDa), aldolase (161 kDa) and catalase (232 kDa). After 
centrifugation at 39.000 rpm for 20 h at 4°C in a Beckman SW40 rotor (200,000g average, 
Beckman Instruments), gradients were divided into 18 fractions of about 650µl each, and the 
precipitate at the bottom of the tube was solubilized with 650µl of SDS-PAGE loading buffer. 
Equal volume (usually 40µl) of each fraction and the solubilized precipitate were analysed on SDS-
PAGE. 
2.2.7 SDS-PAGE and Protein Blot  
For protein blot, the protein samples, extracted in presence or absence of reducing agent, were 
denaturated in 3X SDS-PAGE loading buffer (20mM Tris-Cl pH 8.6, 1% (w/v) SDS, 10% (v/v) 
glycerol, 0,17% (w/v) bromophenol blue and 4% (v/v) 2-ME) and incubated 5 min at 95°C. 
Proteins were separated by SDS-PAGE, using a 15% (v/v) acrylamide gel and using an unstained 
protein molecular weight markers (Unstained Protein Molecular Weight Marker, Thermo 
Scientific). Proteins were then transferred to nitrocellulose membrane (Protran Nitrocellulose 
Transfer Membranes, Perkin Elmer), stained with Ponceau-S staining solution (0,1% (w/v) 
Ponceau-S in 5% (w/v) trichloroacetic acid) to check correct transfer and quantity of proteins and 
washed in water. For immunoblotting experiments, the membrane was successively incubated in T-
TBS (137mM NaCl, 20mM Tris-Cl and 0,2% (v/v) Triton X-100), supplemented with 1% (w/v) 
Fetal Bovine Albumin (FBS) and 0.02% NaN3, containing primary antibody anti-FLAG (1:2.000 
(Sigma)). After incubation, the membrane was washed with T-TBS and incubated with T-TBS 
supplemented with 5% (w/v) powder-milk containing secondary anti-Rabbit antibody (horseradish 
peroxidase (HRP) conjugated (1:18.000 (Pierce)) and washed twice with T-TBS and once with 
TBS (137mM NaCl, 20mM Tris-Cl). The membrane was then treated with enhanced 
chemiluminescent (ECL) HRP substrate (SuperSignal West Pico chemiluminescence substrate, 
Thermo Scientific) according to manufacturers’ protocol. The signal was detected with Amersham 
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Hyperfilm (GE HealthCare) or with ChemiDOC Digital Instrument (Bio-Rad). Relative and 
absolute signal intensity for bands were quantified using Image-Lab (Bio-Rad). 
2.3 DNA Methods 
2.3.1 Polymerase Chain Reaction (PCR) 
Typical PCR 273 mixture was composed of 1ng DNA matrix, 50 nmol dNTP mix, 40pmol of each 
primers, 1 U of DNA polymerase (DreamTaq DNA Polymerase, Thermo Scientific) and 2,5µl of 
10X polymerase buffer in a total volume of 25µl. Reactions were incubated 5 min at 94°C, before 
being subjected to 35 cycles of amplification: 30 sec at annealing temperature (according to 
primers) and 1 min/amplified kb at 72°C. A final cycle of 5 min at 72°C was performed to promote 
complete elongation. 
2.3.2 Digestion, Ligation, DNA Purification and Quantification 
Restriction enzymes were used for both preparative digestion (prior to ligation) and analytical 
digestion (after mini or maxi DNA preparation). Typically, plasmidic DNA, from 100ng (for 
analytical test digestion) up to 500ng (for preparative digestion), was incubated with specific 
restriction enzymes with corresponding buffer (supplemented with BSA when required) in a total 
volume of 20 or 50µl. Digestion mixes were incubated for 1 hour or more at the proper 
temperature. 
Digested plasmids were ligated using a 5:1 insert/plasmid ratio. DNA was mixed with 1 U of T4 
ligase (New England BioLabs) in corresponding buffer for a total volume of 20µl and incubated at 
least 24 h at room temperature. Usually, half of the ligation product was used for E. coli 
transformation. 
Agarose gels were prepared with 0,8 to 1,5% (w/v) agarose melted in TBE buffer (89mM Tris-Cl 
pH 8.0, 89mM H3BO3, 20mM EDTA) containing 0.05% (w/v) ethidium bromide. DNA samples 
were mixed with 6X DNA loading buffer (40% (v/v) glycerol, 0.25% (w/v) bromophenol blue) and 
loaded on gels, besides a DNA ladder mix (GelRulerTM, Fermentas). DNA was visualised on an 
ultraviolet transilluminator (UviDoc, Uvitec Cambridge). 
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Quantification was performed by visual comparison with DNA ladder mix or by measurement with 
a spectrophotometer (NanoDrop 2000c UV/IV Spectrophotometer ,Thermo Scientific). 
For purification of DNA fragments from agarose gels, DNA bands were cut out from gel and 
DNA was extracted and purified using QIAquick Gel Extraction Kit (Qiagen) according to 
manufacturers’ instructions. Briefly, agarose bands were mixed with proper quantity (2 volume of 
buffer to 1 volume of gel) of QC (1.0M NaCl, 50mM MOPS, pH 7.0, 15% (v/v) isopropanol) 
buffer and incubated at 50°C until complete agarose melting. Resulting solution was filtrated 
through the column by centrifugation (1 min at 11.000g) and washed twice. DNA was then eluted 
with 30 – 50µl of distilled water. The eluted was finally checked on agarose gel and quantified. 
2.3.3 Chemical Competent Escherichia coli DH5-α Cells: 
Preparation and Transformation 
A 2ml pre-culture of E. coli DH5-α competent cells, grown over night in LB medium (Duchefa 
Biochemie) at 37°C, was used to inoculate 100ml of LB medium. Cells were grown in a shaking 
incubator to an OD600 of 0,4 and then cooled down for 30 min on ice. Cells were collected by 
centrifugation at 4000rpm for 10 min at 4°C and resuspended in 50ml of 100mM CaCl2, 70mM 
MgCl2 and 40mM NaOAc pH 5.5. After incubation for 45 min on ice, cells were pelleted by 
centrifugation at 4000rpm for 10 min at 4°C and resuspended with 5ml of 100mM CaCl2, 70mM 
MgCl2, 15% (v/v) glycerol and 40mM NaOAc pH 5.5. Cell preparation was divided into 100 - 
200µl aliquots that were incubated on ice for 1 h, then frozen in liquid nitrogen and stored at -
80°C. 
For transformation, aliquots of competent cells were mixed with half of the ligation product and 
incubated 20 min on ice. Cells were heat shocked 2 min at 42°C and then diluted in 1 ml LB 
medium. After 1 h at 37°C different quantity of cells were plated on LB Agar medium (Duchefa 
Biochemie) supplemented with selective antibiotic (100 µg/ml of ampicillin for pDHA vector, 100 
µg/ml of kanamycin for pGreen vector). Cells were grown overnight at 37°C. 
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2.3.4 Competent Agrobacterium tumefaciens GV3101 Cells: 
Preparation and Transformation 
Agrobacterium tumefaciens is a plant pathogen which causes the formation of crown galls or tumours 
in tissues infected by the bacterium 274. Briefly, the determinants for establishing and sustaining 
tumours are located mostly on large Tumour-Inducing (Ti) plasmids. The T-DNA is a discrete 
section of the Ti plasmid bounded by 25 bp imperfect repeats termed the right (RB) and left 
borders (LB). The T-DNA and the virulence (vir) region are two distinct regions of all Ti 
plasmids which are essential for Agrobacterium-mediated plant transformation. The T-DNA is 
transferred to, and integrated in, the host cell nuclear genome at the on-set of infection. The 
processing of the T-DNA and its transfer to the host plant cell nucleus is achieved primarily by the 
concerted action of about 20 vir gene products. Ti plasmid-encoded vir genes can function in trans 
to promote the transfer of T-DNAs from co-resident plasmids to recipient plant cells. Such T-
DNA-containing plasmids are termed Ti vectors. Genes and sequences to be transformed into 
plants are inserted between the LB and RB of the Ti vector T-DNA. 
Agrobacterium GV3101 strain carries a disarmed Ti plasmid that possesses the vir genes needed for 
T-DNA transfer, but has no functional T-DNA region of its own. A single colony was inoculated 
in 3 ml of LB completed with the appropriate antibiotic selection in a 15 ml Falcon tube at 28°C 
overnight on a roller drum. 0.5 - 1 ml of the overnight culture was then inoculated in 100 ml of LB 
and grown at 28°C with vigorous shaking until reaching an OD600 of 0.8 and then cooled down 
for 30 min on ice. Cells were collected in Corex tube and centrifuged at 4000rpm for 10 min at 4°C 
in a JA-20 rotor. Cells pellet was resuspended in ice cod 10% (v/v) glycerol. After 3 cycles of 
resuspension and spin of the cells, the pellet was resuspended in 2.5ml of ice cold 10% (v/v) 
glycerol and divided in 50µl aliquots that were frozen in liquid nitrogen and stored at -80°C. 
A. tumefaciens transformation was performed by electroporation. Competent cells were transferred 
into electroporation cuvettes and 50 - 200ng of DNA were added; the cuvette was placed in the 
GenePulser unit (Bio-Rad), that  was set on 2.4 kV, 25 µFD and 400 Ohm for the resistance, and 
a single pulse of 9 msec was given. Cells were transferred in a 2ml Eppendorf tube with 1ml of LB. 
After 6 h at 28°C different dilutions of the cells were plated on LB Agar medium (Duchefa 
Biochemie) supplemented with selective antibiotic (50 µg/ml gentamicin for pHelper positive 
selection, 25 µg/ml rifampicin for GV3101 strain selection, 5 µg/ml tetracycline for pSoup vector 
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selection and 100 µg/ml kanamycin for pGreen selection). Cells were grown for at least 36h at 
28°C. 
2.3.5 DNA-Mini and Maxi Preparation 
DNA mini-preparations were performed using the QIAfilter Plasmid Mini Kit (Qiagen) and 
following the manufacturers’ instructions. E. coli cells from a 2 ml culture in LB (Duchefa 
Biochemie) were collected by centrifugation at maximal speed for 1 min. Cells were resuspended in 
250µl of P1 buffer (10mM EDTA, 100 µg/ml RNase A, 50mM Tris-Cl pH 8.0) and lysed by 
addition of 250µl of P2 buffer (200mM NaOH, 1% (w/v) SDS). After 5 min of incubation protein 
were precipitated by addition of 350µl of N3 buffer (3M potassium acetate pH 5.0) and a 
centrifugation of 1 min at maximal speed. Supernatant was then filtrated through a QIAfilter 
column and washed twice with PE buffer; DNA was then eluted with 35 – 50µl of distilled water 
and quantified. 
For DNA maxi-preparation QIAfilter Plasmid Maxi Kit (Qiagen) was used, following the 
manufacturers’ instructions. Starting from a pre cultured 400ml LB culture, cells were collected by 
centrifugation at 6000g for 15 min, resuspended in 10 ml of P1 buffer and lysed by adding 10 ml of 
P2 buffer. After an incubation of 5 min, proteins were precipitated by adding 10 ml of P3 buffer 
(3M potassium acetate pH 5.0) and filtered through a QIAfilter Maxi Cartridge. Cell lysate was 
then loaded into a QIAfilter column, previously equilibrated with QBT buffer (750mM NaCl, 
50mM MOPS pH7.0, 15% (v/v) isopropanol, 0.15% (v/v) Triton X-100). After washing twice the 
resin with 30 ml of QC buffer (1.0M NaCl, 50mM MOPS, pH 7.0, 15% (v/v) isopropanol), DNA 
was eluted with 15 ml of QF elution buffer (1.25M NaCl, 50mM Tris-Cl, pH 8.5, 15% (v/v) 
isopropanol) and precipitated by addition of 10 ml isopropanol and a centrifugation at 15.000 g for 
30 min at 4°C. The resulting pellet was washed with 70% (v/v) ethanol, precipitated and dried. 
DNA was finally resuspended in distilled water and quantified. 
2.3.6 Colony Screen by Cracking Procedure 
20µl of E. coli cells cultured overnight in LB (Duchefa Biochemie) were added to 20µl of 2X 
cracking solution (100mM NaOH, 10mM EDTA, 1% (w/v) SDS, 10% (v/v) glycerol, 0.5% (w/v) 
bromocresol green) and mixed vigorously. After 5 min at room temperature the samples were 
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mixed with 6X DNA loading buffer (40% (v/v) glycerol, 0.25% (w/v) bromophenol blue) and 
loaded on gels. DNA was visualised on an ultraviolet transilluminator (UviDoc). 
2.4 Plasmids and Constructs 
2.4.1 Plasmids 
i. pUC57 
pUC57 is a cloning vector commonly used in E. coli. The vector length is 2.710 bp and is isolated 
from E. coli strain. ER-BMP2/N-BMP2 fusion construct was synthesized and cloned in this vector 
from GeneCust (GeneCust Europe, Laboratoire de Biotechnologie du Luxembourg S.A.). 
ii. pDHA 
The plasmid pDHA was derived from the Cauliflower Mosaic Virus (CaMV) 35S gene expression 
cassette pDH51 275 as follows: An EcoRV – BamHI fragment from pDH51 incorporating the 3' 
proximal nucleotides of the CaMV 35S promoter was replaced with a similar fragment from 
pAMV9 276 in which the 3' end of the CaMV 35S promoter was fused to the 5’ untranslated region 
of the coat protein mRNA from alfalfa mosaic virus. This sequence has been reported to enhance 
the translatability of messenger RNA 277. The expression vector pDHA 271,278 was used for cloning 
experiment and for transient expression in tobacco protoplasts. 
iii. pGreen 
For replication in A. tumefaciens, the pSa replication locus has been used in the pGreen vector. 
Sequencing of this fragment showed that the pSa replication locus consists of an Ori and RepA 
gene. Some experiments established that the pSa-RepA gene can act in trans on the Ori and is not 
needed on the pGreen vector, offering a substantial saving on the size of the binary vector. 
Therefore, pSa-RepA was subcloned replacing the T-DNA region. The gene coding for bacterial 
resistance to kanamycin, was replaced with the tetracycline resistance gene (Tet) to create pSoup 
(Figure 8) 274.  
The pGreen vector (Figure 8) is based on the general-purpose pBluescript cloning vector 279 and 
therefore contains a Ori for replication in E. coli. The plasmid’s ampicillin resistance gene was 
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replaced with the gene encoding for kanamycin resistance, the pSa-Ori was inserted, the f1 Ori and 
Lac Z’ region deleted and a Bgl II site was left for the introduction of a T-DNA cassette. 
A T-DNA cassette containing the pBluescript SKII LacZ’ gene and multiple cloning sites, flanked 
by synthetic LB and RB sequences and with an additional T-DNA transfer enhancer motif 
immediately adjacent and external to the RB, was inserted to create pGreen. 
The expression vector pGreen 272,273 was used for cloning experiment and for stable expression of 
ER-BMP2 and N-BMP2 in tobacco plants. 
 
2.4.2 ER-BMP2 and N-BMP2 constructs 
A single chimeric construct was ordered to GeneCust (GeneCust Europe, Laboratoire de 
Biotechnologie du. Luxembourg S.A.) in order to obtain the two ER-BMP2 and N-BMP2 final 
constructs with specific restriction enzymes (Figure 9). This was possible thanks to an Afl II 
enzyme site, that is present into the BMP-2 mature domain, that permitted a subcloning 
procedure. The FLAG epitope was added to both constructs, to allow easy immunodetection. The 
synthetic chimeric construct (1707 bp long) was optimized for tobacco expression and cloned from 
GeneCust (GeneCust Europe, Laboratoire de Biotechnologie du Luxembourg S.A.) into a pUC57 
vector with EcoR V restriction enzyme. 
 
Figure 8: pSoup and pGreen binary vector system structure. 
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The two constructs were finally inserted into pDHA vector for cloning experiment and for 
transient expression in tobacco protoplasts and in pGreen vector for constitutive expression under 
the 35S promoter in plants. 
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Figure 9: nucleotide and aminoacidic sequences of the chimeric construct inserted in the pUC57 
vector by GeneCust and used to obtain the final constructs used for transformation. γ-zein N-
terminal is represented in light blue, BMP-2 coding sequence is represented in green and FLAG 
epitope is yellow. The restriction enzymes used for cloning experiments are written above 
respective sites. 
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3.1 Transient Expression of Recombinant Human BMP-2 in 
Tobacco Protoplasts 
The first part of this project consisted of the designing and cloning of the two recombinant BMP-2 
constructs. Tobacco protoplast were then transiently transformed with the two constructs inserted 
in the pDHA vector and after 24h total protein were extracted and analyzed in order to detect the 
presence and the main characteristics of the two recombinant proteins. 
3.1.1 ER-BMP2 and N-BMP2 are Soluble, Not Secreted Proteins 
Due to the presence of γ-zein N-terminal – which is able to induce the formation of insoluble PB 
even when fused to other proteins of the secretory pathway 258 – in the chimeric protein, ER-
BMP2 was expected to be insoluble in absence of reducing agent. 
For this reason, to determine the presence and the molecular weight of ER-BMP2 and N-BMP2 
produced by transient transformation, after protoplasts homogenisation under both reducing and 
non-reducing conditions, samples were centrifuged at 4000g for 10 min and both the supernatants 
(S) – were the soluble proteins are collected – and pellets (P) – were the insoluble polymers are 
collected – were analyzed by SDS-PAGE and protein blot using anti-FLAG antiserum (Figure 
12a). Since N-BMP2 is a secreted protein, the medium where protoplast were incubated were also 
analyzed, according to the same procedure (Figure 12b). Protoplasts transformed with the empty 
vector were used as control (CTRL).  
In absence of reducing agent ER-BMP2 migrates mainly as a soluble dimer of about 55 kDa 
(Figure 12a, band D), that is disassembled in presence of 2-ME, when only the monomer was 
observed (Figure 12a, bands M). 
N-BMP2 was poorly solubilized in the absence of 2-ME and migrated at 60 kDa (Figure 12a, 
empty circle), slower than expected; conversely, in the presence of 2-ME, a band of the expected 
monomeric mobility, about 40 kDa, was detected (Figure 12a, band M). 
Both proteins appear to be soluble even in the absence of 2-ME, as demonstrated by the low 
intensity of the bands detected in the pellet samples (Figure 12a, P lanes), which are probably due a 
residual of supernatants after centrifugation. ER-BMP2 was detected in higher amount than N-
BMP2 inside protoplasts (Figure 12a, compare ER-BMP2 with N-BMP2 lanes).  
The band at 25 kDa (dark arrowhead) detected in every lane is present also in the control samples 
and it is probably an unrelated polypeptide that reacts with the secondary antibody. 
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Neither ER-BMP2 nor N-BMP2 were detected in the incubation medium, indicating that both 
proteins was not secreted (Figure 12b). 
 
 
 
Figure 12: ER-BMP2 and N-BMP2 are soluble proteins and are not secreted in the protoplast medium. 
Total protein from 20.000 transformed protoplasts (A) and their medium (B) were extracted in the presence 
(+) or absence (-) of the reducing agent 2-mercaptoethanol (2ME) in the homogenization buffer. After 
centrifugation, the supernatants (S), which contains soluble proteins, and pellets (P), which contains 
insoluble polymers, were analyzed by SDS-PAGE and protein blot. The migration of molecular weight 
standards (kDa) is indicated.  
A 
B 
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Figure 13: ER-BMP2 and N-BMP2 are soluble proteins. Protein blot performed on an independent 
experiment of transient transformation. Total protein of 20.000 protoplasts were extracted in the presence (+) 
or absence (-) of the reducing agent 2-mercaptoethanol (2ME) in the homogenization buffer; after 
centrifugation to separate insoluble polymers, the supernatants were analyzed by SDS-PAGE and protein 
blot. The migration of molecular weight standards (kDa) is indicated. 
 
In order to confirm the obtained results an independent transformation experiment (Figure 13) was 
performed. 
ER-BMP2 dimers (D) migrated mainly at 55 kDa, while their monomers (M) migrate at 
approximately 35 kDa. When protein extraction was performed in reducing condition a band of 
about 20 kDa (Figure 13, asterisk), that may correspond to a degradation product, was detected. 
N-BMP2 is confirmed to have a lower level of expression than ER-BMP2 and a monomeric form 
of about 45 kDa detectable in the presence of reducing agent (M).  
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3.1.2 ER-BMP2 is N-Glycosylated and Retained in the ER 
ER-BMP2 has a predicted N-glycosylation site in the BMP-2 mature domain (see N338ST 
sequence in Figure 9). However, not all glycosylation consensus sites are really glycosylated, 
because they can be masked by folding 280.  
Endoglycosidase H enzyme is able to remove N-linked mannose-rich oligosaccharides from a 
polypeptidic chain unless these are modified by Golgi enzymes and it is therefore used for in vitro 
experiments in order to demonstrate traffic through the Golgi complex 281. Thus, to verify if ER-
BMP2 was correctly glycosylated and to assess whether the presence of the γ-zein portion induced 
ER retention and accumulation of the chimeric protein, an Endoglycosidase H assay was 
performed. 
Total proteins were extracted from transfected protoplasts in presence of reducing agent and 
incubated (Figure 14 – lanes +) or not (Figure 14 – lanes -) with EndoH enzyme. Samples were 
analyzed with SDS-PAGE and immunoblot.  
The removal of the N-glycan caused a shift in ER-BMP2 mobility (Figure 14, compare 
electrophoresis mobility in lanes - and + (black arrowhead)) indicating that most probably the 
fusion protein does not traffic through the Golgi complex but instead remains in the ER, as 
expected. 
  
Figure 14: Endoglycosidase H assay on ER-BMP2 transformed protoplasts. Proteins extracted from 20.000 
wild-type (CTRL) and ER-BMP2 transformed protoplasts were treated (+) or not (-) with Endoglycosidase 
H (EndoH) and analyzed by SDS-PAGE and protein blot. The migration of molecular weight standards 
(kDa) is indicated. 
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3.1.3 ER-BMP2 Does Not Form Large Polymers in the ER 
It is demonstrated that γ-zein N-terminal domain is able to induce the formation of large insoluble 
polymers (PB) which accumulate within the ER, even when fused to other protein, as 
demonstrated for zeolin 258,282. When these proteins were subjected to a sucrose velocity gradient 
centrifugation they were completely recovered in the pellets fraction.  
Total proteins from 400.000 protoplasts transformed with ER-BMP2 construct (Figure 15a) were 
extracted in the absence of reducing agent and then subjected to sedimentation velocity 
centrifugation on a continuous 5-25% (w/v) sucrose gradient. Aliquots of gradient fractions and of 
material precipitated at the bottom of tube (P) were analyzed by SDS-PAGE and protein blot 
using anti-FLAG antiserum. 
ER-BMP2, unlike γ-zein, forms polymers in the range of 50-150 kDa (Figure 14a) that don’t 
reach the pellet fraction.  
3.1.4 N-BMP2 is a Monomer 
The same experiment was performed on proteins extracted from protoplasts transformed with N-
BMP2 (Figure 15b) construct. 
N-BMP2 migrated as a monomeric peptide of about 60 kDa (Figure 15b - see also empty circle in 
Figure 12a). 
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3.2 Transgenic Tobacco Plants Expressing rhBMP-2 
On the basis of the promising results obtained with the experiments of transient expression in 
protoplasts, transgenic Tobacco plants expressing ER-BMP2 and N-BMP2 were generated by 
Agrobacterium-mediated transformation of plant tissues (leaf-discs). As described in chapter 2.1.3, 
plants were transformed with Agrobacterium tumefaciens  strain GV3101 carrying the plasmid of 
interest. 
Leaf disk were incubated in a suspension of A. tumefaciens and then placed on MS medium 
supplemented with the correct combination of hormones – to induce shoot and roots generation – 
and antibiotics – to select transformed cells and remove remaining bacteria. After 4-6 weeks on 
selective medium, plants were tested for protein expression and transferred in soil. Plants with high 
expression levels were propagated and new generations were screened and selected for high and 
stable expression of recombinant proteins. 
3.2.1 Transgenic Tobacco Plants Production and Transformants 
Selection 
ER-BMP2 and N-BMP2 were expressed in transgenic tobacco under the control of the 
constitutive CaMV 35S promoter via Agrobacterium tumefaciens-mediated transformation. 
Expression levels and patterns of transgene inheritance generally show wide variation between 
independently transformed plants carrying the same construct and many factors can contribute to 
these variations; these include integration site, transgene copy number and transgenic locus 
configuration 283. Thus, several putative transgenic lines, selected on the basis of their hygromycin 
resistance, were tested for ER-BMP2 and N-BMP2 accumulation by protein blot analysis of equal 
amounts of leaf extracts.  
ER-BMPs accumulation was not homogeneous in the analyzed plants, however, considering an 
equal volume of leaf analyzed, ER-BMP2 showed a clear tendency to accumulate at higher levels 
than N-BMP2 (Compare Figure 16a and 16b).  
Five lines with the highest protein accumulation levels were selected for each construct from a 
population of 13 N-BMP2 (Figure 16a) and 20 ER-BMP2 (Figure 16b) primary transformants 
and used in all subsequent experiments to further characterize protein expression in tobacco leaves. 
When the shoots were about 4 weeks old they were transferred and grown in soil. The seeds 
produced from every transgenic plant were collected and stored; while seeds of 3 selected ER-
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BMP2 transformants (ER7, ER23 and ER27 – Figure 16b, black arrows), selected according to 
their high accumulation levels, were propagated in order to generate F1 transgenic plants. 
 
 
 
 
 
 
 
Figure 16: Screening of tobacco transgenic F0 plants. Young leaves of transformed shoots were homogenised 
in the presence of the reducing agent in SDS-PAGE loading buffer at 95°C. After centrifugation the 
supernatants were diluted 1:10 for N-BMP2 transformed shoots (A) or 1:20 for ER-BMP2 transformed 
shoots (B) and analyzed by SDS-PAGE and protein blot with anti-FLAG antiserum.   
A) N-BMP2 
B) ER-BMP2 
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3.2.3 ER-BMP2 Accumulates to Higher Level than N-BMP2 in 
Transgenic Tobacco 
In order to determine the expression levels and the main characteristics of ER-BMP2 and N-
BMP2 in transgenic plants, total protein extracts were analyzed by protein blot.  
Total proteins were extracted in ice-cold homogenisation buffer supplemented with protease 
inhibitor in presence or absence of 2-ME. The homogenates were then centrifuged and 
supernatants were collected. Total proteins in supernatants were quantified using the Bradford 
protein assays and diluted for SDS-PAGE and immunoblotting analysis. 
N-BMP2 plants in previous experiments demonstrated a lower expression level than ER-BMP2 
plants, hence a 10 time higher amount of total proteins were used (Figure 18). 
In ER-BMP2 expressing plants, in non reducing conditions one main band was detected, 
corresponding to the dimeric form of the protein (Figure 18, ER-BMP2 section, lanes -), while in 
presence of reducing agent, monomers (M) of approximately 35 kDa were detected (Figure 18 – 
ER-BMP2 section, lanes +). Even in stable transformation when 2-ME was added to the 
homogenisation buffer a band of about 20 kDa (Figure 18 – ER-BMP2 section, asterisks), that 
may correspond to a degradation product, was detected (compared to Figure 13, asterisk). Almost 
all ER-BMP2 tested transgenic lines demonstrated a good level of protein expression and 
accumulation, even if it was highly variable (data not shown). 
N-BMP2 plants showed a clear tendency to accumulate lower level of protein than ER-BMP2 
plants, thus, a 10 fold amount of total protein extracts were analyzed; for this reason an increased 
detection of non-specific bands could be expected. Even if in absence of reducing agent a putative 
monomeric band of about 60 kDa (Figure 18 - N-BMP2 section, white circle), that change its 
mobility in reducing conditions (Figure 18 - N-BMP2 section, M), was detected. The intricate 
pattern of bands of non-expected molecular weight, that could be due not only to non-specific 
detection but also to a degradation of the protein, makes the interpretation of the results uncertain.  
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Figure 18: ER-BMP2 is Soluble in Transgenic Tobacco Plants. Total protein from two N-BMP2 
transformed plants, two ER-BMP2 transformed plants and two wild type plants (CTRL) were extracted 
from young leaves in the presence (+) or absence (-) of the reducing agent 2-mercaptoethanol (2-ME) in the 
homogenization buffer. After centrifugation to separate insoluble polymers, the supernatants were analyzed 
by SDS-PAGE and protein blot with anti-FLAG antiserum: 30µg of total protein of N-BMP2 samples and 
3µg of ER-BMP2 samples were loaded on gel with the same quantity of control samples. The migration of 
molecular weight standards (kDa) is indicated. 
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3.2.1 ER-BMP2 Is N-Glycosylated and Retained in the ER 
As described before, ER-BMP2 has a predicted site for N-glycosylation in the BMP-2 mature 
domain that in transient expression experiments demonstrated to be sensible to Endoglycosidase H 
enzyme. Total proteins extracts obtained from transgenic plants in presence of 2-ME were 
incubated (+) or not (-) with EndoH to demonstrate ER-BMP2 sensitivity to the enzyme and thus 
its retention in the ER. 
The removal of the single ER-BMP2 N-glycan by Endoglycosidase H (Figure 22, compare 
electrophoresis mobility in lanes - and +) indicated that most probably the fusion protein did not 
traffic through the Golgi complex, but remained in the ER, as expected.  
 
Figure 22: ER-BMP2 is retained in the ER of transgenic leaves. Total proteins from leaves collected from a 
ER-BMP2 transgenic plant and a wild-type plant (CTRL) were extracted in the presence of reducing agent 
2-ME and 8 µg of samples were treated (+) or not (-) with Endoglycosidase H (EndoH). Samples were then 
analyzed by SDS-PAGE and protein blot with anti-FLAG antiserum. The migration of molecular weight 
standards (kDa) is indicated. 
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3.2.1 ER-BMP2 Is a Soluble Protein That Forms Large Oligomers 
Experiments conducted on transiently transformed tobacco protoplasts demonstrated that ER-
BMP2, unlike γ-zein, is a mainly soluble protein present mostly in a dimeric form, even 
considering the formation of higher polymers.  
To investigate its assembly grade in stable transformation, total protein from young leaves 
harvested from one transgenic ER-BMP2 plant were extracted in absence of reducing agent and 
then subjected to sedimentation velocity centrifugation on a continuous 5-25% (w/v) sucrose 
gradient. Aliquots of gradient fractions and of precipitates at the bottom of tube were analyzed by 
SDS-PAGE and protein blot.  
ER-BMP2 expressed in transgenic plants confirmed to be a soluble protein that presents a dimeric 
form (Figure 21, peak around 66 kDa); nevertheless, ER-BMP2 was able to form high polymers 
that exceeded the 231 kDa marker. As hypothesized in section 3.1.3, the different solubility of ER-
BMP2 and γ-zein is possibly due to a kind of interference between the 6 cysteines of γ-zein and the 
7 ones of BMP-2 mature domain that formed unexpected inter- and intra-chain bonds; despite 
this, the formation of large oligomers is not precluded.  
 
 
Figure 21: ER-BMP2 forms large oligomers. Leaves collected from one ER-BMP2 plant (ER23) were 
homogenised in absence of reducing agent and 800µg of total protein extract were analyzed with a 
sedimentation velocity centrifugation on a continuous 5-25% (w/v) sucrose gradient. Aliquots of gradient 
fractions and of material precipitated at the bottom of tube (P) were analyzed by SDS-PAGE and protein 
blot using anti-FLAG antiserum. Top of gradient is on the left, numbers on top of the gel indicate the 
molecular mass of markers in kDa. The migration of molecular weight standards (kDa) is indicated at left. 
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3.2.2 ER-BMP2 Accumulates in Seeds 
Zeins are a class of prolamin proteins account for more than 70% of maize endosperm protein 284. 
Because ER-BMP2 is a fusion protein that includes the N-terminal of γ-zein prolamin, the 
presence of recombinant protein in seeds was investigated. Tobacco seeds produced by Wild-Type 
tobacco, N-BMP2 and ER-BMP2 F0 transformed plants were homogenised in SDS-PAGE 
Laemmli buffer at 95°C and centrifuged in order to remove seeds debris. Supernatants were then 
collected and analyzed with SDS-PAGE and immunoblot. Specific signal were detected in 3 of 4 
ER-BMP2 analyzed samples (Figure 19 – ER-BMP2, ER5, ER7 and ER27, dark arrowhead). 
ER4 did not show a detectable signal, probably due to a too low level of expression. 
 
Figure 19: ER-BMP2 accumulates in tobacco seeds This protein blot was performed on 0.05g of seeds 
collected from 1 wild type (CTRL), 4 N-BMP2 and 4 ER-BMP2 plants. seeds were homogenised in SDS-
PAGE loading buffer at 95°C. Ratio volume of buffer/weight of the seeds was 10/1. After centrifugation 5µl 
of the supernatants were collected – avoiding the oil phase – and analyzed with SDS-PAGE and protein blot 
with anti-FLAG antiserum. The migration of molecular weight standards (kDa) is indicated. 
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3.2.3 Young Leaves Produces Higher Level of ER-BMP2 Compared 
to Older Ones. 
In many cases the accumulation of recombinant protein demonstrated to be sensitive to the age and 
the dimension of the leaf, with younger leaves showing better performance than the older ones 
285,286. Thus a protein blot experiment was conducted in order to investigate if the levels of 
expression of ER-BMP2 could change with respect to the age and the dimension of the leaf. Total 
proteins were extracted from 8 leaves of an ER-BMP2 plant (ER23), chosen from those who 
demonstrated higher levels of expression during previous experiments, and a SDS-PAGE 
experiment was performed using anti-FLAG antibody. The dimensions of each harvested leaf are 
shown in the table below. The proteins were extracted in ice-cold homogenisation in absence of 2-
ME and, after protein quantification, 4µg of each samples were analyzed. 
The gel showed an overall downward trend. Youngest leaves (Figure 20 – lanes 1and 2) showed a 
significantly higher level of expression compared to the older ones (Figure 20 – compare lane 7and 
8 with lane 1 and 2), that were larger, thinner and that presented barely detectable bands. 
 
Figure 20: Young leaves produces higher level of protein compared to older ones. The protein blot was 
performed on leaves collected from one F0 ER-BMP2 plant. Total protein of 8 leaves of different age and 
size (see the table) were extracted in absence of 2-ME and 4µg of total protein of each sample were loaded on 
acrylamide gel together with wild-type leaf extract (CTRL) and analyzed by protein blot. Numbers on top of 
the lane indicate the position of the leaf: n°1 was the smallest leaf closest to the top, n°8 was instead the 
biggest one in the lower part of the plant. The migration of molecular weight standards (kDa) is indicated. 
Lane n° 1 2 3 4 5 6 7 8 
Size (cm) 3.0x1.5 3.2x1.8 4.2x2.2 4.8x3.5 7.0x5.5 9.3x6.0 11.7x8.2 12.4x9.3 
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3.2.4 Quantification of ER-BMP2 
Absolute quantification of produced ER-BMP2 was performed by comparison of progressive 
dilutions of leaf extracts with known amounts of the commercial standard protein Flag–BAP, a 49 
kDa fusion protein commercialized by Sigma-Aldrich (Figure 23a and b). To set-up the 
experiment, a first blot was done to compare the results obtained from quantifications performed 
on samples extracted in the presence or absence of 2-ME, in order to check if the presence of 
reducing agent leads to a better results. 
Total proteins were extracted in ice-cold homogenisation buffer in the absence (Figure 23a) or 
presence (Figure 23b) of 2-ME; the homogenates were then centrifuged and supernatants were 
collected. Total proteins in supernatants were quantified using the Bradford protein assays and 
diluted and different amount (from 0.5 to 4µg) were analyzed for SDS-PAGE and 
immunoblotting with anti-FLAG antiserum. Absolute signal intensity of bands were quantified 
using Image-Lab (see Table below). 
The calibration curves results, normalized for the different molecular weight of Flag-BAP standard 
(49 kDa) and of ER-BMP2 bands, indicated that ER-BMP2 appeared to be about 40ng on 4µg of 
total protein, representing around 1% of total soluble proteins (TSP), regardless the presence of 2-
mercaptoethanol in the homogenization buffer. The higher absolute quantification (table) obtained 
on sample extracted in absence of reducing agent is probably due to the smeared signal, which was 
resolved in more discrete bands in the presence of 2-ME. 
 
 
Figure 23: Absolute quantification of ER-BMP2 in transgenic leaves. Total proteins from leaves collected 
from one ER-BMP2 transgenic plant(ER23) were extracted in absence (Left blot, A) or presence (Right 
blot, B) of reducing agent 2-ME and progressive dilutions of leaf extracts were analyzed by SDS-PAGE and 
protein blot with anti-FLAG antiserum together with known amounts of the standard protein Flag–BAP. 
numbers on the top of the lanes indicate the amount of total proteins analyzed. The migration of molecular 
weight standards (kDa) is indicated. 
A B 
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Another protein blot experiment was performed in order to assess the amount of ER-BMP2 
produced by different plants. Four micrograms of leaf extracts from 7 different ER-BMP2 
expressing plants were analyzed on SDS-PAGE and protein blot. Signal intensities were compared 
to known amounts of the commercial standard protein Flag–BAP. Absolute quantification results 
demonstrate an high variability between each plant production levels with the amount of detected 
ER-BMP2 ranging from 0.5 to 2.5% of total proteins (see the table below). 
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3.2.5 rhBMP-2 Active Domain (rhBMP2-AD) is Efficiently 
Recovered on Thrombin Cleavage 
To use rhBMP2 as a pharmaceutical, it will be necessary to minimize the extra sequences that are 
present in ER-BMP2; for this purpose, the accessibility of the thrombin cleavage site was 
investigated. Total protein were extracted in the presence of the reducing agent 2-mercaptoethanol 
in the homogenization buffer and, after incubation (+) or not (-) with thrombin, samples were 
analyzed by SDS-PAGE and protein blot using anti-FLAG antiserum. 
The fusion protein ER-BMP2 (Figure 24 – ER-BMP2 lanes) was efficiently cleaved by thrombin 
(Figure 24 – lanes +), and the rhBMP2-AD (asterisk) was, in most part, released by thrombin 
cleavage in a 20 kDa form. Internal relative quantifications, performed with Image-Lab software, 
indicated that the released polypeptide includes about 50% of the non digested lane, indicating a 
sufficiently good accessibility to thrombin. 
 
Figure 24: rhBMP2-AD is efficiently recover by thrombin cleavage. Total proteins from leaves, harvested 
from two ER-BMP2 transgenic plants (ER27 and ER7) and one Wild-Type plant (CTRL), were extracted 
in presence of reducing agent 2-ME and 20 or 25µg of samples were incubated (+) or not (-) with thrombin 
(Thr, 8U). Samples were then analyzed by SDS-PAGE and protein blot with anti-FLAG antiserum. 
Numbers on the top of the lanes indicate the amount of total proteins analyzed. The migration of molecular 
weight standards (kDa) is indicated. 
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3.2.6 Quantification of rhBMP2-AD 
Absolute quantification of the rhBMP2-AD bands (Figure 25, 
asterisks) was performed using Image-Lab. Results were 
normalized for the different molecular weight of Flag-BAP 
standard compared to the molecular weight of the BMP-2 mature 
peptide. The software indicated that the fragments appeared to be 
3.5ng/20µg for ER27 lane and 5.5ng/25µg for ER7 lane. 
These results indicate that the amount of mature BMP-2 peptide 
in these plants was about 0.02% of total soluble protein. 
 
 
 
An assessment of the yield of rhBMP2 for every g of fresh leaves was performed for ER27 and 
ER7 plants: 
ER27: 3.5µg of rhBMP2 mature domain obtained for 1g of fresh leaves harvested. 
ER7: 6,4 µg of rhBMP2 mature domain obtained for 1g of fresh leaves harvested. 
This is a good results, however the high variability of the expression levels of each plant must be 
considered: choose plants with a higher level of expression may lead to an increase of the amount of 
recovered protein and to even better results. 
 
  
Figure 25: Absolute quantification of rhBMP2 active domain. 
Detail of Figure 24, total proteins of two transgenic plant, ER27 
(first 2 lanes, 20µg) and ER7(second part of the blot, 25µg) were 
treated (+) or not (-) with thrombin and analyzed with SDS-PAGE 
and immunoblotting. 
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4 Discussion 
  
Valentina Ceresoli – R09501 
 
Production of Human Recombinant Differentiation Factors in Transgenic Tobacco Plants 
D
is
cu
ss
io
n
 
86 
4.1 Overview 
Bone morphogenetic proteins (BMPs) have been demonstrated to be effective for the treatment of 
bony defects, fracture repair and non-unions, but, due to the low yield, the limited amounts of 
source material and the potential risk of disease transmission, purified native BMPs are not suitable 
for large scale use. Furthermore, the yield of BMPs produced by recombinant expression in 
mammalian cells is relatively low compared to other recombinant protein production systems, and 
this make their use in common clinical applications extremely costly. 
In this study, in order to improve rhBMP2 accumulation levels using a plant-based system, a γ-
zein/BMP2 chimeric construct – expected to be retained and accumulated in the endoplasmic 
reticulum – was synthesized by transient and stable transformation experiments and characterized. 
The level of accumulation and the main characteristics of this construct were then compared to the 
native form of the protein. 
4.2 ER-BMP2 and N-BMP2 Expression and Characterization 
SDS-PAGE and protein blot experiments performed both on transiently transfected protoplasts 
and on transgenic plants tissues, showed a clear tendency of ER-BMP2 to accumulate at high 
levels. This result confirmed the ability of γ-zein to induce protein accumulation in cells and proved 
the non-recognition of the chimeric protein by the ER quality control system. The ER, indeed, has 
the function of controlling successful folding and assembling of the newly synthesized proteins and 
of delivering to the degradation pathways those polypeptides that do not meet expected 
requirements. Consequently, this property of the reticulum may be a serious drawback when the 
aim is to increase ER accumulation of secretory proteins. Previous results showed that when γ-zein 
N-terminal was fused to cytosolic protein Nef, it was unable to prevent the degradation of this 
protein; instead, when a fusion on Nef to the complete zeolin sequence (consisting of the N-
terminal of γ-zein fused to the C-terminal of phaseolin 258) was performed, the protein avoided the 
degradation and formed PBs 287. All these data suggest that besides the necessary role of the 
hydrophobic regions and the Cysteine residues of zein 265 another kind of stabilization may be 
needed in order to avoid degradation early after synthesis and provide enough time to start PB 
assembly 271,287. In the ER-BMP2 case, this mechanism can be accomplished by the 7 Cysteines of 
BMP-2 mature domain, which may form inter-chain bonds able to stabilize the structure and 
promote the formation of polymers. 
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During immunoblot experiments, ER-BMP2 demonstrated to be a soluble N-glycosylated protein 
that, in non reducing conditions, migrates mainly in a dimeric form which is disassembled in 
monomers of approximately 35 kDa in the presence of reducing agent. Moreover, the presence of 
2-ME in the homogenisation buffer led to detection of a further band of about 20 kDa; this 
particular band demonstrated to be N-glycosylated and sensitive to EndoH treatment, but its 
molecular weight was not affected by thrombine treatment. Such findings suggest that most 
probably this band corresponds to a specific C-terminal product of degradation on ER-BMP2, but 
it is unknown if it will conserve its activity after purification. 
Accordingly to the original design of ER-BMP, in order to obtain a correct glycosylated rhBMP2-
AD that could be used for pharmaceutical and clinical purposes, a final ER localization mediated 
by PBs formation was expected. Indeed, locating a recombinant protein in the ER of a plant based 
system has two main advantages: the first one is protecting the protein from protease degradation, 
the second one is to obtain a correct N-glycosylated protein. As described before, plant 
glycosylation presents some differences respect to the human counterpart. In plants the N-
glycosylation starts in the endoplasmic reticulum by the co-translational transfer of an 
oligosaccharide precursor to specific Asparagine residues of the nascent polypeptide chain; the 
processing of this oligosaccharide into high-mannose-type, paucimannosidic-type, hybrid-type or 
complex-type N-glycans occurs in the secretory pathway as the glycoprotein moves out from the 
ER to its final destination. At the end of their maturation, some plant N-glycans have typical 
structures that differ from those found in mammalian by the absence of sialic acid 288 and the 
presence of β(1,2)-xylose and α(1,3)-fucose residues289. These plant glyco-epitopes are of major 
interest in the context of the production of proteins dedicated to human therapy because they could 
be immunogenic in mammals 290 and could be involved in allergic reactions 291. The localization of 
ER-BMP2, which has a glycosylation site in its mature domain, is therefore an important issue for 
its future applications. Even if the carbohydrate moiety does not appear to be essential for 
biological activity of BMPs, since the deglycosylated proteins are still capable of inducing bone 
formation in vivo 141, the lack of such modification leads to a decrease in solubility of proteins and 
may lead to misfolding of the final product 143. Given the results on ER-BMP2 solubility, the 
localization of the protein was investigated by Endoglycosidase H assay. This experiment 
demonstrated that the protein has an unmodified N-glycan that is sensitive to the enzyme and, 
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accordingly, ER-BMP2 is not only properly post-translationally modified, but is also located 
within the endoplasmic reticulum. 
 
As described before, γ-zein N-terminal fragment induces the formation of insoluble PBs even 
when it is fused to other proteins of the secretory pathway, like the C-terminal of phaseolin 258,267. 
For this reason the solubility of ER-BMP2 in the absence of reducing agent was an unexpected 
result and its ability to form large polymers was further investigated using sucrose velocity gradient 
centrifugation. Nevertheless, even if ER-BMP2 is mainly present in the dimeric form, the protein 
is able to form larger oligomers (up to 250 kDa). This different behavior of the chimeric protein 
respect to γ-zein and zeolin proteins may be due to a kind of unexpected interaction between the 
two portions of ER-BMP2. Indeed, it is possible that the 6 cysteines of the γ-zein portion and the 
7 ones of BMP-2 mature domain interfere each other in spite of the presence of the DNA-linker, 
that fails its function of ensuring independent folding of the peptides. 
The final recovery of the protein from the expression host is one of the most significant drawbacks, 
both in terms of costs and final productivity, in non-secreted recombinant protein production. To 
accumulate recombinant proteins in insoluble PBs provides an advantage because, by virtue of their 
high density, they can be easily isolated from crude cell or tissue extracts by sucrose density 
gradients fractioning or by low-speed direct centrifugation of the homogenates 265. Because of the 
solubility of ER-BMP2 this methodology is not a feasible option and a different strategy is 
required. One viable option could be an affinity chromatography purification performed with 
specific antibodies; for example, if the protein will be purified using a anti-γ-zein antibody, the 
recovery of the BMP-2 active domain will be easier, since it will be released in the supernatant 
while the γ-zein portion will remain bound to the antibody 252. 
 
Seed storage proteins have unique characteristics that allow very high accumulation during seed 
development 261. Based on their specific features, like assembly, solubility, and intracellular 
localization, they can be divided into three major classes: albumins, globulins and prolamins 292. 
Prolamins form large polymers that rapidly become insoluble and do not proceed along the 
secretory pathway, accumulating as protein bodies within the ER lumen of endosperm cells and 
consequently in seeds 261. When γ-zein, which is one of the most ancient maize prolamins, is 
individually expressed in vegetative tissues of transgenic plants it forms homotypic PBs within the 
ER, indicating that it contains all the necessary information to form an ER-retained polymer 264. 
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For these reasons, the presence of ER-BMP2 – which contains the N-terminal portion of γ-zein 
and forms oligomers in the ER – in the seeds was investigated. Even if the accumulation level was 
not as high as that of γ-zein in maize seeds, probably due to a competition between the chimeric 
protein and the endogenous tobacco storage proteins, the accumulation of ER-BMP2 in seeds per 
se is a promising result. Indeed, there are significant advantages in directing the expression of a 
recombinant protein into the plant seed. In fact, unlike leaf tissues, which consists mostly of water 
and fiber, seeds have a low content of water, offer high stability and natural microencapsulation, 
and are capable to high accumulation of non-endogenous proteins. Even if seeds have evolved to 
store precise amounts of proteins at maximum density within storage cells and consequently leaving 
little space for additional products resulting from transgene expression, there are some strategies 
that lead to an increased degree of storage substance plasticity. For example, it is possible to 
redirect a significant part of the protein synthesis capacity from the production of intrinsic seed 
proteins to the synthesis of foreign proteins, by silencing one of more genes of endogenous storage 
proteins. In this way the recombinant protein of interest could accumulate at higher levels in seeds, 
exceeding the 8% of the total soluble proteins of seeds 293, without compromising their ability to 
germinate 293. 
 
Compared to ER-BMP2, N-BMP2 demonstrated a lower level of accumulation with barely 
detectable bands in immunoblot performed on transgenic plants extracts.  
When immunoblotting experiments were performed on transiently transformed protoplast, a 
monomeric form of N-BMP2, that changed its mobility according to the presence of reducing 
agent, could be detected. The mobility shift of the monomer was probably due to a rearrangement 
of the intra-chain disulphide bonds caused by the presence of 2-ME, or maybe, the presence of 
BMP-2 pro-peptide prevented the correct folding of the protein. 
Conversely, immunoblotting experiments performed on transgenic plants extracts resulted in an 
intricate pattern of bands of non-expected molecular weight. This could be due to non-specific 
detection caused by an high amount of total proteins analyzed and/or to a degradation of the 
protein, that creates a number of bands of different molecular weight. 
These results suggest a combination of adverse factors that led to a low level of transcription. One 
factor that could be involved in the low expression levels might be the presence of the native human 
signal peptide of the protein, that may be not effective in a vegetable system. Another possibility is 
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the addressing of N-BMP2 towards the degradation pathway, due to misfolding or to an incorrect 
processing during protein synthesis.  
All the collected data indicate that without a further strategy that leads to an increased level of 
accumulation and, in case of secretion, bypasses the issues of the modified glycosylation out of the 
ER, the production of a native form of the BMP-2 protein in transgenic plants is not a viable 
option. 
4.3 ER-BMP2 Quantification 
Absolute quantification of produced ER-BMP2 was performed on different plant’s extracts and 
results indicate a highly variable yield. On the average, ER-BMP2 represents about the 1% of total 
leaf soluble proteins, a value that is usually considered as high accumulation in vegetative tissues of 
transgenic plants, even if it is not as high as the 3.5% obtained from zeolin transgenic plants 252. 
The first quantification experiment, performed on total proteins extracted in the presence and in 
the absence of the reducing agent in order to make a comparison on the amount of protein 
obtained, indicated that there was no significant difference in protein amount between the 
extraction procedures. For this reason further quantification analyses were performed on protein 
samples extracted in the absence of 2-ME. The data obtained from these plants were highly 
variable, ranging from 0.5% to more than 2.5%. However, it is known that the expression levels of 
recombinant proteins may show wide variations between independently transformed plants carrying 
the same construct, and that several factors, including integration site, transgene copy number and 
transgenic locus configuration, can contribute to these variations 283. For this reason, besides the 
accurate screening and selection of the plants with the highest level of expression, it is also possible 
to apply strategies that may improve these levels, for example selecting plants with multiple copies 
of the gene of interest. 
 
However, plant-derived recombinant proteins, produced in transgenic tobacco plants and extracted 
directly from leaves, are generally produced at low levels, typically about the 0.1% of the total 
soluble protein 230. This low level of production reflects a combination of factors, with poor protein 
folding and stability among the most relevant, specific for every recombinant protein 294,269. 
Nevertheless, in the recent years, other strategies have permitted an higher accumulation of 
recombinant proteins; for example, a tobacco chloroplast system of expression has been used to 
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produce human proteins, like Human Serum Albumin, getting very solid results 295. Even if our 
results do not reach such levels, they still represent a good starting point that can be further 
improved with the implementation of the strategies adopted. 
After demonstrating the accessibility of the thrombin cleavage, the amount of rhBMP2 active 
domain recovered from 1g of fresh leaves was assessed in two different plants. The best 
performance achieved was 6,4µg of rhBMP2-AD every g of fresh leaves. Considering the high 
variability of the expression levels, this is a good result which can still be improved by selecting 
plants with even better levels of accumulation or maybe trying to direct the protein to other cellular 
compartments, given the excellent results recently achieved, for example, in tobacco chloroplasts 295. 
Because plant-based techniques do not require the same expensive investments as other production 
methods, once the initial costs due to the F0 transgenic production have been overcome, the 
propagation of plants implies a reduced financial impact. Rough calculations based on our results 
suggest that, considering the size and biomass of the greenhouse-produced tobacco plants, in order 
to obtain the amount of rhBMP2-AD which is contained in a single commercial Infuse® kit, only 
one ER-BMP2 tobacco plant is required.  
4.4 Future Perspectives 
The outbreak of Ebola virus disease has highlighted the potential advantages of plant-based 
production systems. Indeed, to develop a vaccine that would be appropriate for human use, three 
different mouse monoclonal antibodies (mAbs) directed against three distinct Ebola virus 
glycoprotein epitopes were chimerized with human constant regions of antibodies and, in order to 
evaluate a more cost-effective and scalable alternative to production in (CHO) cells, they were 
produced in a Nicotiana benthamiana-based antibody manufacturing platform 296. This system 
allows rapid, scalable production of mAbs in less than a month. Moreover, via the use of a 
transgenic strain of N. benthamiana in which plant-specific glycosyltransferases (α(1,3)-
fucosyltransferase and β(1,2)-xylosyltransferase) are inhibited by RNA interference (RNAi), the 
derived mAbs have homogenous mammalian glycans 297. Due to more and more encouraging 
results, plant based pharmaceuticals are finally reaching a wide acceptance, and clinical trials 
investigating their effectiveness have multiplied (Table 4). It is important to think about a great 
advantage of plant-made pharmaceuticals: their cost-benefits advantages can allow more capital to 
Valentina Ceresoli – R09501 
 
Production of Human Recombinant Differentiation Factors in Transgenic Tobacco Plants 
D
is
cu
ss
io
n
 
92 
be invested in research and development of new therapeutics, bringing an overall advantage to the 
society. 
 
Nowadays the diversity of plant-based systems contrasts with the small number of microbial and 
animal-cell platforms regarded as industry gold standards; this can be considered as a strength in 
terms of innovation for product-specific requirements, but also as a drawback in terms of 
standardization and regulatory harmonization. Indeed, the limited number of approved production 
facilities correlates with the relatively small number of plant-derived pharmaceutical products that 
reached the market or are undergoing clinical development.  
Table 4: plant-derived pharmaceutical products assessed in clinical studies 
Company Products Main Application Current Status 
Protalix 
Elelyso Gaucher’s ERT 
FDA-approved in US, 
not in Europe 
α-Galactosidase Fabry ERT Phase I/II 
Oral 
Glucocerebrosidase 
Gaucher’s ERT Phase II 
Ventria 
Lactoferrin 
Antibiotic-associated diarrhea, anti-
inflammatory 
Phase II 
VEN120 Inflammatory bowel disease Phase I 
VEN130 Osteoporosis Phase I 
Biolex LocteronTM HCV Phase II/IIb 
Icon Genetics 
NHL vaccine HSV/HIV Phase I/II 
MAPP66 Monoclonal antibodies Phase I 
Medicago 
H5 Pandemic influenza vaccine 
Phase II/III, approved 
for emergency use 
H5 intradermal Pandemic influenza vaccine Phase I 
Seasonal influenza 
vaccine 
Seasonal influenza vaccine Phase I 
Planet 
Biotechnology 
CaroRX Anti-caries antibody 
Approved as medical 
device 
Fraunhofer IME HIV antibody Microbicide Phase I 
Fraunhofer 
CMB 
HA vaccine Vaccine Phase I 
VAXX/Arizona 
State University 
NoroVAXX Vaccine Phase I 
MAPP ZMapp Ebola antibody cocktail 
Emergency use,  
Phase I expected soon 
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*Data extracted from Sack et al., 2015 298 
Nevertheless, finally something is changing. Elelyso is a transgenic suspended carrot cells expressed 
form of the glucocerebrosidase enzyme that has been approved from FDA for injection and 
indicated for long-term enzyme replacement therapy for adults with a confirmed diagnosis of 
Gaucher disease 299. 
Moreover, in order to avoid the lengthy and costly regulatory procedures for FDA approval, several 
companies have established commercial platforms for the production of non-pharmaceutical 
products, even in order to generate a revenue 298. For example TrypZean™ is a recombinant bovine 
trypsin, sold by Sigma-Aldrich company, that is produced in corn and is sold for research 
purposes300. Another example is ORF Genetics, that in 2007 have introduced a next generation of 
human growth factors and cytokines produced in the endosperm tissue of the barley grain and 
marketed under the brand name ISOkine™. 
 
After the necessary tests that assess an in vitro effectiveness of the protein, also rhBMP-2 protein 
produced in Tobacco transgenic plants might find its primary market as a non-pharmaceutical 
products. This market strategy would avoid the time required for regulatory procedures and 
guarantee time necessary for a first assessment of its effectiveness after a scale up of protein 
production,  creating a framework for its possible further use in clinical practice. Moreover, in the 
last years BMP-2 have been demonstrated to play key roles as neurotrophic factor, by regulating 
the development of the nervous system and its maintenance in adulthood, drawing attention to its 
potential use in the treatment of neurodegenerative diseases 301,302. For these reasons, the possibility 
to use the recombinant BMP-2 protein at a reduced cost, not only in the studies on osteogenic 
differentiation, but also for those on innovative therapies, could have a positive impact on its 
market. Because Italy don’t allow the cultivation of transgenic plants for commercial purpose, the 
first step required must be the recruitment of a foreign company that has the possibility to perform 
a scale-up of the protein production, in order to obtain it in quantity that allow a large scale 
effectiveness tests. 
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5 Conclusions 
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The poor yield of recombinant human BMPs in mammalian cell culture systems led to the 
investigation of a method to enhance the production of these proteins. The addition of γ-zein N-
terminal domain to the BMP-2 mature domain sequence resulted in a significant increase of 
accumulation of the protein in plant tissues while showing no negative effects on cell viability and 
plant growth. 
Total protein extracts from transgenic plants showed high levels of ER-BMP2 accumulation, 
which were even higher if compared to those of N-BMP2 plants. 
Cleavage of mature BMP-2 domain using the thrombine enzyme also demonstrated promising 
results: mature BMP-2 proteins were observed after incubation with the enzyme; however,  the 
biological activity of the rhBMP2-AD has to be further investigated. 
In summary, producing and accumulating recombinant human BMP-2 in the ER of transgenic 
tobacco plants demonstrated to be a safe, rapid and simple strategy that significantly enhances its 
recovery during the extraction procedure. Nevertheless, further investigations on the biological 
activity of this BMP-2 on different cell cultures and in vivo tests are needed before a potential 
commercialization of this production strategy might take place. 
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